<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Mar Drugs</journal-id><journal-id journal-id-type="iso-abbrev">Mar Drugs</journal-id><journal-id journal-id-type="publisher-id">marinedrugs</journal-id><journal-title-group><journal-title>Marine Drugs</journal-title></journal-title-group><issn pub-type="epub">1660-3397</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5666421</article-id><article-id pub-id-type="doi">10.3390/md15100313</article-id><article-id pub-id-type="publisher-id">marinedrugs-15-00313</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Conotoxins as Tools to Understand the Physiological Function of Voltage-Gated Calcium (Ca<sub>V</sub>) Channels</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ram&#x000ed;rez</surname><given-names>David</given-names></name><xref ref-type="aff" rid="af1-marinedrugs-15-00313">1</xref><xref ref-type="aff" rid="af2-marinedrugs-15-00313">2</xref></contrib><contrib contrib-type="author"><name><surname>Gonzalez</surname><given-names>Wendy</given-names></name><xref ref-type="aff" rid="af1-marinedrugs-15-00313">1</xref><xref ref-type="aff" rid="af3-marinedrugs-15-00313">3</xref></contrib><contrib contrib-type="author"><name><surname>Fissore</surname><given-names>Rafael A.</given-names></name><xref ref-type="aff" rid="af4-marinedrugs-15-00313">4</xref></contrib><contrib contrib-type="author"><name><surname>Carvacho</surname><given-names>Ingrid</given-names></name><xref ref-type="aff" rid="af5-marinedrugs-15-00313">5</xref><xref rid="c1-marinedrugs-15-00313" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-marinedrugs-15-00313"><label>1</label>Centro de Bioinform&#x000e1;tica y Simulaci&#x000f3;n Molecular, Universidad de Talca, 3460000 Talca, Chile; <email>davramirez@utalca.cl</email> (D.R.); <email>wgonzalez@utalca.cl</email> (W.G.)</aff><aff id="af2-marinedrugs-15-00313"><label>2</label>Instituto de Ciencias Biom&#x000e9;dicas, Universidad Aut&#x000f3;noma de Chile, 3460000 Talca, Chile</aff><aff id="af3-marinedrugs-15-00313"><label>3</label>Millennium Nucleus of Ion Channels-Associated Diseases (MiNICAD), Universidad de Talca, 3460000 Talca, Chile</aff><aff id="af4-marinedrugs-15-00313"><label>4</label>Department of Veterinary and Animal Sciences, University of Massachusetts, Amherst, MA 01003, USA; <email>rfissore@umass.edu</email></aff><aff id="af5-marinedrugs-15-00313"><label>5</label>Department of Biology and Chemistry, Faculty of Basic Sciences, Universidad Cat&#x000f3;lica del Maule, 3480112 Talca, Chile</aff><author-notes><corresp id="c1-marinedrugs-15-00313"><label>*</label>Correspondence: <email>icarvacho@ucm.cl</email>; Tel.: +56-71-220-3518</corresp></author-notes><pub-date pub-type="epub"><day>13</day><month>10</month><year>2017</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2017</year></pub-date><volume>15</volume><issue>10</issue><elocation-id>313</elocation-id><history><date date-type="received"><day>08</day><month>8</month><year>2017</year></date><date date-type="accepted"><day>04</day><month>10</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; 2017 by the authors.</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Voltage-gated calcium (Ca<sub>V</sub>) channels are widely expressed and are essential for the completion of multiple physiological processes. Close regulation of their activity by specific inhibitors and agonists become fundamental to understand their role in cellular homeostasis as well as in human tissues and organs. Ca<sub>V</sub> channels are divided into two groups depending on the membrane potential required to activate them: High-voltage activated (HVA, Ca<sub>V</sub>1.1&#x02013;1.4; Ca<sub>V</sub>2.1&#x02013;2.3) and Low-voltage activated (LVA, Ca<sub>V</sub>3.1&#x02013;3.3). HVA channels are highly expressed in brain (neurons), heart, and adrenal medulla (chromaffin cells), among others, and are also classified into subtypes which can be distinguished using pharmacological approaches. Cone snails are marine gastropods that capture their prey by injecting venom, &#x0201c;conopeptides&#x0201d;, which cause paralysis in a few seconds. A subset of conopeptides called conotoxins are relatively small polypeptides, rich in disulfide bonds, that target ion channels, transporters and receptors localized at the neuromuscular system of the animal target. In this review, we describe the structure and properties of conotoxins that selectively block HVA calcium channels. We compare their potency on several HVA channel subtypes, emphasizing neuronal calcium channels. Lastly, we analyze recent advances in the therapeutic use of conotoxins for medical treatments. </p></abstract><kwd-group><kwd>conotoxins</kwd><kwd>voltage-gated calcium (Ca<sub>V</sub>) channels</kwd><kwd>&#x003c9;-conotoxin structure</kwd><kwd>therapeutic potential</kwd></kwd-group></article-meta></front><body><sec id="sec1-marinedrugs-15-00313"><title>1. Introduction</title><p>Venomous cone snails (<italic>Conus</italic>) produce several toxic peptides, conopeptides, which target the neuromuscular system of their prey, worms, mollusks, snails and fishes [<xref rid="B1-marinedrugs-15-00313" ref-type="bibr">1</xref>,<xref rid="B2-marinedrugs-15-00313" ref-type="bibr">2</xref>]. Conotoxins are peptides of 20&#x02013;30 residues whose main structural characteristic is a rigid backbone formed by disulfide bonds between six cysteines. Conotoxins can be classified according to several criteria, including: <italic>a.</italic> the gene superfamily they belong to; <italic>b.</italic> the pattern of cysteine distribution, cysteine framework; and <italic>c.</italic> their molecular targets. <xref ref-type="table" rid="marinedrugs-15-00313-t001">Table 1</xref> summarizes the known groups of conotoxins and their protein targets.</p><p>The toxins produced by the genus <italic>Conus</italic> are numerous and diverse, and approximately 6200 different toxins have been isolated and identified from more than 100 different species thus far [<xref rid="B14-marinedrugs-15-00313" ref-type="bibr">14</xref>,<xref rid="B15-marinedrugs-15-00313" ref-type="bibr">15</xref>]. The target of most of these toxins are ion channels, including voltage- and ligand-gated channels, as well as G-protein coupled receptors [<xref rid="B16-marinedrugs-15-00313" ref-type="bibr">16</xref>,<xref rid="B17-marinedrugs-15-00313" ref-type="bibr">17</xref>]. In this review, we will focus on &#x003c9;-conotoxins, which modulate Ca<sub>V</sub>2.X channels. &#x003c9;-conotoxins prevent entry of calcium (Ca<sup>2+</sup>) through these voltage-activated Ca<sub>V</sub>, channels at the presynaptic nerve terminal, thereby, interfering with the release of vesicles containing acetylcholine and neurotransmission [<xref rid="B13-marinedrugs-15-00313" ref-type="bibr">13</xref>]. In general, &#x003c9;-conotoxins impede Ca<sup>2+</sup> flux by physically occluding the channel pore [<xref rid="B18-marinedrugs-15-00313" ref-type="bibr">18</xref>]. The kinetics of the binding is variable and can show slow dissociation rates, generating poorly reversible blockage and long term inhibition [<xref rid="B18-marinedrugs-15-00313" ref-type="bibr">18</xref>].</p><sec id="sec1dot1-marinedrugs-15-00313"><title>1.1. Voltage-Gated Calcium Channels</title><p>Voltage-gated Ca<sup>2+</sup> (Ca<sub>V</sub>) channels are transmembrane proteins that belong to the same transmembrane gene superfamily as the Na<sub>V</sub> and the K<sub>V</sub> channels. Ca<sub>V</sub> channels can be organized into two groups according to the voltage changes required for activation: Ca<sup>2+</sup> channels that require &#x0201c;larger&#x0201d; depolarizations to be opened (when compared with the current-voltage relation for <italic>I<sub>Na</sub></italic>) are known as high-voltage activated (HVA) channels, whereas Ca<sup>2+</sup> channels that open at more negative potentials are known as low-voltage activated (LVA) [<xref rid="B19-marinedrugs-15-00313" ref-type="bibr">19</xref>]. Ca<sub>V</sub>s are composed of a pore forming subunit, &#x003b1;<sub>1</sub>, encoded by the CACNA1x genes (see <xref ref-type="table" rid="marinedrugs-15-00313-t002">Table 2</xref>). L-Type Ca<sub>V</sub>s, Ca<sub>V</sub>1.1&#x02013;1.4, are known as &#x003b1;<sub>1</sub>S, &#x003b1;<sub>1</sub>C, &#x003b1;<sub>1</sub>D, and &#x003b1;<sub>1</sub>F. The P/Q-, N- and R-type, Ca<sub>V</sub>2.1&#x02013;Ca<sub>V</sub>2.3, are termed as &#x003b1;<sub>1</sub>A, &#x003b1;<sub>1</sub>B, and &#x003b1;<sub>1</sub>E. Finally, the T-Type, Ca<sub>V</sub>3, are composed of &#x003b1;<sub>1</sub>G, &#x003b1;<sub>1</sub>H, and &#x003b1;<sub>1</sub>I (<xref ref-type="table" rid="marinedrugs-15-00313-t002">Table 2</xref> [<xref rid="B20-marinedrugs-15-00313" ref-type="bibr">20</xref>,<xref rid="B21-marinedrugs-15-00313" ref-type="bibr">21</xref>]). Depolarizations provoked by the opening of Ca<sub>V</sub> channels shape the action potential in the heart, regulate muscle contraction, and modulate neurotransmitter secretion at nerve terminals. In general, &#x0201c;<italic>excitable cells translate their electricity into action by Ca<sup>2+</sup> fluxes modulated by voltage-sensitive, Ca<sup>2+</sup>-permeable channels</italic>&#x0201d; [<xref rid="B19-marinedrugs-15-00313" ref-type="bibr">19</xref>]. Once Ca<sup>2+</sup> ions gain access to the cytosol, they act as second messengers, capable of binding thousands of proteins affecting their localization and function. Variations of intracellular Ca<sup>2+</sup> concentrations influence many cell functions such as transcription, motility, apoptosis and initiation of development [<xref rid="B22-marinedrugs-15-00313" ref-type="bibr">22</xref>].</p><p>The expression and properties of the pore forming &#x003b1; subunit are modified by two main auxiliary or accessory subunits: &#x003b1;<sub>2</sub>&#x003b4; and &#x003b2;, which regulate the channel&#x02019;s biophysical properties, its trafficking, and membrane expression. Ca<sub>V</sub>1 and Ca<sub>V</sub>2 channels can form heteromeric complexes co-assembling with different &#x003b1;<sub>2</sub>&#x003b4; subunits, which are encoded by <italic>CACNA2D1-4</italic> genes, and &#x003b2; subunits, which are encoded by <italic>CACNB1-4</italic> genes. The stoichiometry of this assembly is of one &#x003b2; subunit and one &#x003b1;<sub>2</sub>&#x003b4; accessory subunit. An additional accessory subunit, &#x003b3;, has been reported only in skeletal muscle [<xref rid="B20-marinedrugs-15-00313" ref-type="bibr">20</xref>].</p></sec><sec id="sec1dot2-marinedrugs-15-00313"><title>1.2. Ca<sub>V</sub>2.X Channels</title><p>The channels of the Ca<sub>V</sub>2 family is formed by a pore-forming Ca<sub>V</sub>&#x003b1;1 subunit plus the auxiliary subunits Ca<sub>V</sub>&#x003b2; and Ca<sub>V</sub>&#x003b1;<sub>2</sub>&#x003b4;, with the Ca<sub>V</sub>&#x003b1;1 subunit defining the channel subtype, as shown previously (see <xref ref-type="table" rid="marinedrugs-15-00313-t002">Table 2</xref>). The Ca<sub>V</sub>2.1 channels conduct currents classified as P-type and Q-type that are well described in neurons, whereas the Ca<sub>V</sub>2.2 and Ca<sub>V</sub>2.3 channels underpin the N-type and R-type currents, respectively, also characterized in neurons [<xref rid="B23-marinedrugs-15-00313" ref-type="bibr">23</xref>].</p><p>Ca<sub>v</sub>2 channels are responsible for the Ca<sup>2+</sup> influx required for the fast release of neurotransmitters as well as for the release of hormones from secretory-type cells such as chromaffin cells [<xref rid="B24-marinedrugs-15-00313" ref-type="bibr">24</xref>]. Ca<sub>V</sub>2 channels also regulate neuronal excitability via activation of the Ca<sup>2+</sup> activated K<sup>+</sup> channels that in turn control repolarization and hyperpolarization [<xref rid="B25-marinedrugs-15-00313" ref-type="bibr">25</xref>]. Consistent with these functions, Ca<sub>V</sub>2.1 null mice exhibit ataxia and die around 4 weeks after birth [<xref rid="B26-marinedrugs-15-00313" ref-type="bibr">26</xref>]. Mice deficient in Ca<sub>V</sub>2.2 channels, N-type, showed suppressed response to pain, which is consistent with the use of conotoxins as analgesics [<xref rid="B27-marinedrugs-15-00313" ref-type="bibr">27</xref>], and with the expression of Ca<sub>V</sub>2.2 channels in nerve terminals in association with pain receptors. Ca<sub>V</sub>2.2 channels are involved in neurotransmitter release of nociceptive pathways from afferent terminals in the ventral and dorsal horn of the spinal cord and dorsal root ganglion neurons [<xref rid="B20-marinedrugs-15-00313" ref-type="bibr">20</xref>,<xref rid="B28-marinedrugs-15-00313" ref-type="bibr">28</xref>]. Ca<sub>V</sub>2.3 null mice also show reduced pain sensitivity [<xref rid="B23-marinedrugs-15-00313" ref-type="bibr">23</xref>].</p></sec><sec id="sec1dot3-marinedrugs-15-00313"><title>1.3. General Properties of &#x003c9;-Conotoxins</title><p>&#x003c9;-conotoxins are small peptides ranging in size from 13 to 30 amino acids. They have net charges between +5 and +7 [<xref rid="B17-marinedrugs-15-00313" ref-type="bibr">17</xref>], are mostly polar and are highly water soluble. They show three disulfide bridges that are formed between conserved cysteine residues that are arranged in the following organization, C-C-CC-C-C [<xref rid="B29-marinedrugs-15-00313" ref-type="bibr">29</xref>]; they form a common structural motif consisting of a cysteine knot, which is also present in toxic and inhibitory polypeptides [<xref rid="B30-marinedrugs-15-00313" ref-type="bibr">30</xref>]. The &#x003c9;-conotoxins family exhibit a characteristic pattern signature described in the PROSITE database [<xref rid="B31-marinedrugs-15-00313" ref-type="bibr">31</xref>,<xref rid="B32-marinedrugs-15-00313" ref-type="bibr">32</xref>] (see <xref ref-type="fig" rid="marinedrugs-15-00313-f001">Figure 1</xref>). </p><p>Most &#x003c9;-conotoxins characterized to date are selective for N-type Ca<sub>V</sub> channels. As indicated, the main mechanism of action of &#x003c9;-conotoxins&#x02019; is by blocking the channel pore [<xref rid="B33-marinedrugs-15-00313" ref-type="bibr">33</xref>], which is accomplished by tight binding of the toxin to the channel pore [<xref rid="B18-marinedrugs-15-00313" ref-type="bibr">18</xref>]. The most studied and defined &#x003c9;-conotoxin is GVIA isolated from <italic>Conus geographus</italic> [<xref rid="B34-marinedrugs-15-00313" ref-type="bibr">34</xref>]. Its specific activity against N-type Ca<sup>2+</sup> channels&#x02014;Ca<sub>V</sub>2.2 channels- [<xref rid="B35-marinedrugs-15-00313" ref-type="bibr">35</xref>] was established in neuronal cell types [<xref rid="B36-marinedrugs-15-00313" ref-type="bibr">36</xref>]. Other &#x003c9;-conotoxins from the venom of different Conus species include CVID from the venom of <italic>Conus catus</italic>, CNVIIA from <italic>Conus consors</italic> and MVIIA, MVIIIV, and MVIID from <italic>Conus magus</italic> have been identified [<xref rid="B37-marinedrugs-15-00313" ref-type="bibr">37</xref>]. Additional &#x003c9;-conotoxins have been isolated from other <italic>Conus</italic> such as <italic>striatus</italic> [<xref rid="B38-marinedrugs-15-00313" ref-type="bibr">38</xref>], and <italic>magus</italic> [<xref rid="B39-marinedrugs-15-00313" ref-type="bibr">39</xref>].</p></sec></sec><sec id="sec2-marinedrugs-15-00313"><title>2. Classification of &#x003c9;-Conotoxins That Target Ca<sub>V</sub> Channels</title><sec id="sec2dot1-marinedrugs-15-00313"><title>2.1. C. geographus&#x02014;GVIA</title><p><bold>GVIA.</bold> It consists of 27 amino acids with a backbone constrained by the formation of three disulfide bonds (Cys<sup>1</sup>&#x02013;Cys<sup>16</sup>, Cys<sup>9</sup>&#x02013;Cys<sup>20</sup>, and Cys<sup>15</sup>&#x02013;Cys<sup>26</sup>). The possible toxic effect of GVIA and of the other members of the family such as GVIB, GVIC, GVIIA, and GVIIB was determined by performing intracerebral injections in mice, which provoked involuntary movements (&#x0201c;shaking&#x0201d;) in the animals [<xref rid="B34-marinedrugs-15-00313" ref-type="bibr">34</xref>] (<xref ref-type="table" rid="marinedrugs-15-00313-t003">Table 3</xref>). In vitro studies were first performed on nerve-muscle preparations of frogs where GVIA irreversible blocked the voltage-activated Ca<sup>2+</sup> channels of the presynaptic terminal preventing acetylcholine exocytosis [<xref rid="B13-marinedrugs-15-00313" ref-type="bibr">13</xref>]. Together, these studies showed that GVIA selectively inhibits Ca<sub>V</sub>2.2 channels in an irreversible manner. The site of action of GVIA on Ca<sub>V</sub>2.2 was found to be on the large extracellular domain III between the S5&#x02013;S6 trans-membrane regions [<xref rid="B18-marinedrugs-15-00313" ref-type="bibr">18</xref>]; mutagenesis studies further showed that the reversibility of the block induced by GVIA and MVIIA was dramatically enhanced by swapping a glycine residue at position 1326 for a proline. GVIA also binds the &#x003b1;1 subunit of the Torpedo nAChR [<xref rid="B13-marinedrugs-15-00313" ref-type="bibr">13</xref>]. The 3D structures of GVIA resolved by NMR spectroscopy deposited in the Protein Data Bank (PDB) are: 2CCO [<xref rid="B40-marinedrugs-15-00313" ref-type="bibr">40</xref>], 1TTL [<xref rid="B41-marinedrugs-15-00313" ref-type="bibr">41</xref>], and 1OMC [<xref rid="B42-marinedrugs-15-00313" ref-type="bibr">42</xref>].</p></sec><sec id="sec2dot2-marinedrugs-15-00313"><title>2.2. C. magus&#x02014;MVIIA and MVIIC</title><p><bold>MVIIA.</bold> Also known as ziconotide is a 25 amino acid peptide that also blocks the pore of Ca<sub>V</sub>2.2 channels (<xref ref-type="table" rid="marinedrugs-15-00313-t003">Table 3</xref>) and induced potent analgesia in rodents [<xref rid="B43-marinedrugs-15-00313" ref-type="bibr">43</xref>] and human patients with persistent cancer pain [<xref rid="B44-marinedrugs-15-00313" ref-type="bibr">44</xref>]. In December 2004, the Food and Drug Administration (FDA) approved Prialt<sup>&#x000ae;</sup> (commercial name for MVIIA) for the treatment of severe chronic pain using an intrathecal pump system to deliver the drug into the cerebrospinal fluid. Consistent with this action, injection of MVIIA into mammals caused important neuromuscular effects such as decrease of spontaneous and coordinated locomotor activity and tremors [<xref rid="B45-marinedrugs-15-00313" ref-type="bibr">45</xref>]. It was shown that these effects and the pain relief caused by delivery of MVIIA into the cerebrospinal fluid are mediated by inhibition of the release of pro-nociceptive neurochemicals such as glutamate, calcitonin gene-related peptide (CGRP), and substance P into the brain and spinal cord [<xref rid="B46-marinedrugs-15-00313" ref-type="bibr">46</xref>,<xref rid="B47-marinedrugs-15-00313" ref-type="bibr">47</xref>]. Site-mutagenesis studies revealed that the Met<sup>12</sup> residue in loop 2 (<xref ref-type="fig" rid="marinedrugs-15-00313-f002">Figure 2</xref>) is the responsible for the toxicity of MVIIA. Met<sup>12</sup> interacts with the hydrophobic pocket residues Ile<sup>300</sup>, Phe<sup>302</sup>, and Leu<sup>305</sup>, located between repeats II and III of Ca<sub>V</sub>2.2 channels; this interaction disrupts the normal function of the channel [<xref rid="B45-marinedrugs-15-00313" ref-type="bibr">45</xref>]. Systematic mutations of the residues in the loop 2 of MVIIA as well as of other &#x003c9;-conotoxins may be used for future drug design to develop modulators of Ca<sub>V</sub>2.2 with lower side effects and higher effectiveness [<xref rid="B45-marinedrugs-15-00313" ref-type="bibr">45</xref>]. The 3D structures of MVIIA resolved by NMR spectroscopy deposited in the PDB are: 1OMG [<xref rid="B48-marinedrugs-15-00313" ref-type="bibr">48</xref>], 1MVI [<xref rid="B49-marinedrugs-15-00313" ref-type="bibr">49</xref>], 1TTK [<xref rid="B50-marinedrugs-15-00313" ref-type="bibr">50</xref>], 1DW4 [<xref rid="B51-marinedrugs-15-00313" ref-type="bibr">51</xref>], and 1DW5 [<xref rid="B51-marinedrugs-15-00313" ref-type="bibr">51</xref>].</p><p><bold>MVIIC.</bold> This toxin blocks Ca<sub>V</sub>2.1 and Ca<sub>V</sub>2.2 channels (<xref ref-type="table" rid="marinedrugs-15-00313-t003">Table 3</xref>). It possesses similar characteristics to those described for MVIIA and its intracerebral injection in mice caused progressive decrease in respiration rates with marked signs of gasping for breath. The peptide was lethal at low doses (0.1&#x02013;0.4 &#x003bc;g [<xref rid="B52-marinedrugs-15-00313" ref-type="bibr">52</xref>]). The 3D structures of MVIIC resolved by NMR spectroscopy deposited in the PDB are: 1OMN [<xref rid="B53-marinedrugs-15-00313" ref-type="bibr">53</xref>] and 1CNN [<xref rid="B54-marinedrugs-15-00313" ref-type="bibr">54</xref>].</p></sec><sec id="sec2dot3-marinedrugs-15-00313"><title>2.3. C. striatus&#x02014;SVIA and SVIB SO-3</title><p><bold>SVIA and SVIB.</bold> The SVIA toxin contains 24 amino acids. Its administration into lower vertebrates such as fish and frogs provokes paralysis [<xref rid="B38-marinedrugs-15-00313" ref-type="bibr">38</xref>], although it has relatively poor activity against mammalian Ca<sup>2+</sup> channels. While SVIA blocks only Ca<sub>V</sub>2.2, SVIB blocks P/Q type and N-type channels (<xref ref-type="table" rid="marinedrugs-15-00313-t003">Table 3</xref>). SVIB induces respiratory distress in mice when injected intracranially at concentrations of 70 pmol/g mouse and it is lethal around 300 pmol/g mouse; SVIA administration does not kill mice even at extremely high doses [<xref rid="B38-marinedrugs-15-00313" ref-type="bibr">38</xref>]. </p><p><bold>SO-3.</bold> This &#x003c9;-conotoxin shows analgesic activity similar to that of MVIIA when tested in models of acute and chronic pain in rodents, however, it has fewer adverse effects than MVIIA [<xref rid="B45-marinedrugs-15-00313" ref-type="bibr">45</xref>,<xref rid="B55-marinedrugs-15-00313" ref-type="bibr">55</xref>]. The 3D structure of SO-3 resolved by NMR spectroscopy deposited in the PDBe is: 1FYG [<xref rid="B56-marinedrugs-15-00313" ref-type="bibr">56</xref>].</p></sec><sec id="sec2dot4-marinedrugs-15-00313"><title>2.4. C. catus&#x02014;CVID</title><p><bold>CVID.</bold> The sequence of its loop 4 is less conserved than other of &#x003c9;-conotoxins. It displays the highest selectivity for N-type over P/Q- type Ca<sup>2+</sup> channels (radioligand binding assays) [<xref rid="B57-marinedrugs-15-00313" ref-type="bibr">57</xref>] and because of this it has been tested in clinical trials as analgesic [<xref rid="B58-marinedrugs-15-00313" ref-type="bibr">58</xref>]. The 3D of CVID structure resolved by NMR spectroscopy deposited in the PDB is: 1TT3 [<xref rid="B50-marinedrugs-15-00313" ref-type="bibr">50</xref>].</p></sec><sec id="sec2dot5-marinedrugs-15-00313"><title>2.5. C. fulmen&#x02014;FVIA</title><p><bold>FVIA.</bold> It is reported to only be effective against Ca<sub>V</sub>2.2 channels [<xref rid="B59-marinedrugs-15-00313" ref-type="bibr">59</xref>]. The 3D structure of FVIA resolved by NMR spectroscopy deposited in the PDB is 2KM9 (to be published).</p></sec><sec id="sec2dot6-marinedrugs-15-00313"><title>2.6. C. textile&#x02014;TxVII and CNVIIA</title><p><bold>TxVII.</bold> This conopeptide is very hydrophobic and has net negative charge of &#x02212;3. The sequence of TxVII is 58% identical to that of &#x003b4;-conotoxin-TxVIA, which targets Na<sup>+</sup> channels. This toxin blocks the slowly inactivating, dihydropyridine- (DHP-) sensitive current [<xref rid="B60-marinedrugs-15-00313" ref-type="bibr">60</xref>]. The 3D of TxVII structure resolved by NMR spectroscopy deposited in the PDB is: 1F3K [<xref rid="B61-marinedrugs-15-00313" ref-type="bibr">61</xref>].</p><p><bold>CNVIIA.</bold> This toxin is closely related to the CnVIIH toxin (<xref ref-type="table" rid="marinedrugs-15-00313-t003">Table 3</xref>), which possesses an unprocessed final glycine and therefore lacks amidation of its C-terminal end [<xref rid="B62-marinedrugs-15-00313" ref-type="bibr">62</xref>,<xref rid="B63-marinedrugs-15-00313" ref-type="bibr">63</xref>]. CNVIIA blocks Ca<sub>V</sub>2.2 channels but surprisingly it does not block the neuromuscular junction of amphibians. Intracerebroventricular injection of CNVIIA in mice causes shaking movements and mild tremors, depending on dosage, whereas when injected intramuscularly into fish it causes paralysis and death at higher doses [<xref rid="B62-marinedrugs-15-00313" ref-type="bibr">62</xref>].</p></sec></sec><sec id="sec3-marinedrugs-15-00313"><title>3. Structural Characteristics of &#x003c9;-Conotoxins and Blockade Site on the Ca<sub>V</sub> Channels</title><p>&#x003c9;-conotoxins share several structural characteristics that allow them to block multiple Ca<sub>V</sub>s on diverse cell types. Here we explore in detail four well known &#x003c9;-conotoxins, CVID, SVIB, GVIA, and MVIIA, whose 3D structures have been resolved by NMR except for CVID (PDB IDs 1MVJ [<xref rid="B49-marinedrugs-15-00313" ref-type="bibr">49</xref>], 2CCO [<xref rid="B40-marinedrugs-15-00313" ref-type="bibr">40</xref>], and 1MVI [<xref rid="B49-marinedrugs-15-00313" ref-type="bibr">49</xref>], respectively); their multiple sequence alignments as well as their 3D structures are shown in <xref ref-type="fig" rid="marinedrugs-15-00313-f002">Figure 2</xref>. As previously noted, they share four loops and three disulfide bonds (<xref ref-type="fig" rid="marinedrugs-15-00313-f002">Figure 2</xref>A,C), giving them the same structural pattern (<xref ref-type="fig" rid="marinedrugs-15-00313-f002">Figure 2</xref>B). These similarities are evident between CVID and SVIB (RMSD<sub>backbone</sub> = 0.109 &#x000c5;), although they are more subtle between CVID and GVIA (RMSD<sub>backbone</sub> = 1.635 &#x000c5;) (<xref ref-type="fig" rid="marinedrugs-15-00313-f002">Figure 2</xref>D). The main structural differences between loops 2 and 3 (structural difference 1) and 4 (structural difference 2), where &#x003c9;-conotoxins residues are not highly conserved, are highlighted with gray boxes (<xref ref-type="fig" rid="marinedrugs-15-00313-f002">Figure 2</xref>B). Despite the structural similarities, there are differences in the selectivity of targets between these toxins. To understand the selectivity of these toxins at the structural basis, using NMR spectroscopy, researchers have determined the secondary and tertiary structures [<xref rid="B50-marinedrugs-15-00313" ref-type="bibr">50</xref>]. Adams et al. found a correlation between the solvent accessible surface area and the selectivity of &#x003c9;-conotoxins, where the most exposed residue, R10 in MVIIA, play a crucial role in binding to Ca<sub>V</sub>s [<xref rid="B50-marinedrugs-15-00313" ref-type="bibr">50</xref>]. The residue(s) on Ca<sub>V</sub> channels that interacts with &#x003c9;-conotoxins is not yet elucidated, although the extracellular linker region between the P-region and S5 in domain III, the pore of Ca<sub>V</sub>2.2, is reported to be the area where the toxins bind channels [<xref rid="B17-marinedrugs-15-00313" ref-type="bibr">17</xref>,<xref rid="B33-marinedrugs-15-00313" ref-type="bibr">33</xref>]. In this region, G1326 appears to be the essential residue, as its mutation modifies the access of GVIA and MVIIA to the active site [<xref rid="B69-marinedrugs-15-00313" ref-type="bibr">69</xref>].</p><p>The structure-activity relationship (SAR) studies conducted in conotoxins identified key residues involved in the interaction with protein targets as well as identification of specific amino acids involved in their structural arrangement. These studies have been used to design small bioactive mimetics to selectively block Ca<sub>V</sub>2.2 over Ca<sub>V</sub>2.1 channels [<xref rid="B70-marinedrugs-15-00313" ref-type="bibr">70</xref>,<xref rid="B71-marinedrugs-15-00313" ref-type="bibr">71</xref>]. Bioactive mimetics have become promising candidates in the search for novel drugs for the treatment of chronic pain [<xref rid="B21-marinedrugs-15-00313" ref-type="bibr">21</xref>]. For example, based on the 3D structure of MVIIA [<xref rid="B48-marinedrugs-15-00313" ref-type="bibr">48</xref>] and identification of key residues such as K2, R10, L11, Y13, and R21 involved in the binding of MVIIA [<xref rid="B72-marinedrugs-15-00313" ref-type="bibr">72</xref>]. The data collected gave fundamental information for the design of the first bioactive mimetic of MVIIA in 1998, including the draft of small structures to mimic the residues R10, L11, and Y13 [<xref rid="B73-marinedrugs-15-00313" ref-type="bibr">73</xref>]. Although this bioactive mimetic showed poor inhibition against Ca<sub>V</sub>2.2 (19% at 10 &#x003bc;M), a second generation of mimetics was produced and two of these compounds showed promising activities against Ca<sub>V</sub>2.2 (IC<sub>50</sub> = 3.3 and 2.7 &#x003bc;M) [<xref rid="B74-marinedrugs-15-00313" ref-type="bibr">74</xref>]. Since then, others &#x003c9;-conotoxins mimetics have been reported using SAR information [<xref rid="B70-marinedrugs-15-00313" ref-type="bibr">70</xref>,<xref rid="B75-marinedrugs-15-00313" ref-type="bibr">75</xref>,<xref rid="B76-marinedrugs-15-00313" ref-type="bibr">76</xref>].</p></sec><sec id="sec4-marinedrugs-15-00313"><title>4. Therapeutic Uses of Conotoxins</title><p>The therapeutic and pharmacological potential of the conotoxins is well-known [<xref rid="B1-marinedrugs-15-00313" ref-type="bibr">1</xref>,<xref rid="B47-marinedrugs-15-00313" ref-type="bibr">47</xref>,<xref rid="B77-marinedrugs-15-00313" ref-type="bibr">77</xref>]. Nevertheless, their intrinsic physic-chemical and therapeutic characteristics such as molecular weight and low bioavailability due to their susceptibility to peptidase degradation has prevented the widespread use of conotoxins in the clinic. Importantly, and despite these limitations, their ability to selectively bind closely related molecular targets is an important strength of these marine conopeptides. Another advantage of Conotoxins is the diversity of targets, as they can act upon ion channels such as K<sub>V</sub>, Na<sub>V,</sub> and Ca<sub>V</sub> channels, as well as on several G-protein coupled receptors including neurotensin, &#x003b1;-adrenergic, and vasopressin receptors and also on ligand-gated receptors such as AChRs, 5HT3Rs, and NMDARs [<xref rid="B77-marinedrugs-15-00313" ref-type="bibr">77</xref>]. These properties make them excellent candidates to develop new bio-compounds and derivatives against pathologies such as pain, stroke, and convulsive disorders. Especially interesting is their specific affinity for N-type, Ca<sub>V</sub>2.2, Ca<sub>V</sub> channels, which is a useful pharmacological characteristic for the validation of molecular targets, for example, in neuropathic pain. Ca<sub>V</sub>s channel-mediated cellular events can be modulated for therapeutic purposes by direct block of Ca<sub>V</sub>2.2, i.e., small peptides as conotoxins; by activation of GPCRs, or by direct interference with the channel trafficking [<xref rid="B23-marinedrugs-15-00313" ref-type="bibr">23</xref>].</p><p>In nature the proteins targeted by the cone snails on the preys are closely related to the proteins targeted in humans; however small structural and physiological differences can modify the efficacy, selectivity, and potency of conotoxins. Moreover, the target protein in cone snail&#x02019;s preys may serve functions that are distinct to those in humans. Further, in humans and mammals the target proteins may be found in protected physiological spaces such as the Central Nervous System [<xref rid="B77-marinedrugs-15-00313" ref-type="bibr">77</xref>].</p><p>The recent significant progress in the identification of novel pharmacological targets for analgesic drugs designed using natural products has promoted the therapeutic use of conotoxins in pain relief. The main analgesic conopeptide is the &#x003c9;-conotoxin MVIIA (Prialt<sup>&#x000ae;</sup>), which was approved for the management of severe chronic pain [<xref rid="B43-marinedrugs-15-00313" ref-type="bibr">43</xref>,<xref rid="B47-marinedrugs-15-00313" ref-type="bibr">47</xref>]. Prialt<sup>&#x000ae;</sup> is being manufactured and labeled by Jazz Pharmaceuticals and Eisai Limited in the US and the European Union, respectively. Prialt<sup>&#x000ae;</sup> blocks selectively N-type Ca<sub>V</sub> channels through the inhibition of the presynaptic neurotransmitter release [<xref rid="B13-marinedrugs-15-00313" ref-type="bibr">13</xref>,<xref rid="B78-marinedrugs-15-00313" ref-type="bibr">78</xref>]. Prialt<sup>&#x000ae;</sup> attenuates nociception in several animal models such as models of persistent pain [<xref rid="B79-marinedrugs-15-00313" ref-type="bibr">79</xref>], chronic inflammatory pain [<xref rid="B80-marinedrugs-15-00313" ref-type="bibr">80</xref>], neuropathic pain [<xref rid="B81-marinedrugs-15-00313" ref-type="bibr">81</xref>], and postoperative pain [<xref rid="B43-marinedrugs-15-00313" ref-type="bibr">43</xref>]. Prialt<sup>&#x000ae;</sup> showed high effectiveness in morphine tolerant murine models [<xref rid="B82-marinedrugs-15-00313" ref-type="bibr">82</xref>], and prolonged Prialt<sup>&#x000ae;</sup> intrathecal infusion does not produce tolerance to its analgesic effects [<xref rid="B79-marinedrugs-15-00313" ref-type="bibr">79</xref>,<xref rid="B82-marinedrugs-15-00313" ref-type="bibr">82</xref>]. Another &#x003c9;-conotoxin with analgesic activity is CVID (AM336), a conopeptide selective for N-type Ca channels [<xref rid="B83-marinedrugs-15-00313" ref-type="bibr">83</xref>], although it might have greater side effects than MVIIA [<xref rid="B83-marinedrugs-15-00313" ref-type="bibr">83</xref>]. Other conotoxins used in analgesia are Contulakin-G (CGX-1160), MrIA (Xen-2174), Conantokin-G (CGX-1007), Vc1.1 (ACV-1), and MrVIB (CGX-1002) [<xref rid="B77-marinedrugs-15-00313" ref-type="bibr">77</xref>].</p><p>The pharmacological and therapeutically pre-clinical efficacy of MVIIA and CVID, along with the FDA approval of Prialt<sup>&#x000ae;</sup>, have established &#x003c9;-conotoxins (and conotoxins in general) as viable platforms for the design of new and specific drugs to alleviate pain by aiming N-type Ca<sub>V</sub> channels.</p></sec><sec id="sec5-marinedrugs-15-00313"><title>5. Conclusions</title><p>Neuronal Ca<sub>V</sub> channels have potential as targets for treatments of pain and the selectivity of conotoxins for these channels render conopeptides valuable therapeutic tools. &#x003c9;-conotoxins display an inhibitory cysteine knot which is also present in other toxic peptides. This motif, along with other common structural characteristics, is the basis of their potent and selective blocking activity on the pore of Ca<sub>V</sub> channels. A &#x003c9;-conotoxin, MVIIA, has been approved by the FDA for therapeutic use under the commercial name of Prialt<sup>&#x000ae;</sup>. Going forward, however, more widespread applications of conotoxins will require improvements to enhance their transport across the blood-brain barrier as well as modification to increase their chemical stability.</p><p>The association between the structure of &#x003c9;-conotoxins and their activity against Ca<sub>V</sub> channels remains undetermined and such knowledge will be fundamental to improve their use as therapeutic agents. Techniques such as circular dichroism and NMR spectroscopy have been helpful in the development of SAR studies, which have aided in the design of MVIIA [<xref rid="B84-marinedrugs-15-00313" ref-type="bibr">84</xref>], and GVIA [<xref rid="B85-marinedrugs-15-00313" ref-type="bibr">85</xref>] analogues. Additionally, the combination of electrophysiology, computational biophysics approaches, and SAR studies has provided new insights into the molecular binding mechanism of &#x003c9;-conotoxins to their targets. This knowledge now places the drug design processes targeting chronic pain in a robust position to develop novel therapeutic agents. The design of small mimetics requires the identification of the correct scaffolds as well as of key residues to mimic. Towards this end, non-peptide mimetics containing the scaffolds of dendritic, 8-hydroxy-2-(1H)-quinolinone and the 5-hydroxymethyl resorcinol and the residues Leu, Arg, and Tyr, which matched the pharmacophore found in the conotoxin, were developed as MVIIA mimetics and show promissory biological activities against Ca<sub>V</sub>2.2. Conotoxins remain an attractive option for the development of new therapeutic strategies using bioactive mimetics against chronic pain. Nevertheless, additional work involving both experimental and theoretical approaches are needed to unravel at the structural level the mechanisms modulating the protein targets of these peptides.</p></sec></body><back><ack><title>Acknowledgments</title><p>Wendy Gonzalez and David Ramirez want to thank Fondecyt 1140624. The laboratory of Rafael A. Fissore was supported in part by funds from a Hatch-NIFA project # NE-1227 and NIH RO1 #51872. Ingrid Carvacho thanks Matthias Piesche and Nolan Piesche for helpful discussion.</p></ack><notes><title>Author Contributions</title><p>David Ramirez prepared the figures. David Ramirez and Ingrid Carvacho wrote the manuscript. David Ramirez, Wendy Gonzalez, Rafael A. Fissore, and Ingrid Carvacho prepared the manuscript for submission. All authors revised and approved the last version of the article.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-marinedrugs-15-00313"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Becker</surname><given-names>S.</given-names></name><name><surname>Terlau</surname><given-names>H.</given-names></name></person-group><article-title>Toxins from cone snails: Properties, applications and biotechnological production</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2008</year><volume>79</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1007/s00253-008-1385-6</pub-id><?supplied-pmid 18340446?><pub-id pub-id-type="pmid">18340446</pub-id></element-citation></ref><ref id="B2-marinedrugs-15-00313"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terlau</surname><given-names>H.</given-names></name><name><surname>Olivera</surname><given-names>B.M.</given-names></name></person-group><article-title>Conus venoms: A rich source of novel ion channel-targeted peptides</article-title><source>Physiol. Rev.</source><year>2004</year><volume>84</volume><fpage>41</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1152/physrev.00020.2003</pub-id><?supplied-pmid 14715910?><pub-id pub-id-type="pmid">14715910</pub-id></element-citation></ref><ref id="B3-marinedrugs-15-00313"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gray</surname><given-names>W.R.</given-names></name><name><surname>Luque</surname><given-names>A.</given-names></name><name><surname>Olivera</surname><given-names>B.M.</given-names></name><name><surname>Barrett</surname><given-names>J.</given-names></name><name><surname>Cruz</surname><given-names>L.J.</given-names></name></person-group><article-title>Peptide toxins from Conus geographus venom</article-title><source>J. Biol. Chem.</source><year>1981</year><volume>256</volume><fpage>4734</fpage><lpage>4740</lpage><?supplied-pmid 7014556?><pub-id pub-id-type="pmid">7014556</pub-id></element-citation></ref><ref id="B4-marinedrugs-15-00313"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fainzilber</surname><given-names>M.</given-names></name><name><surname>Nakamura</surname><given-names>T.</given-names></name><name><surname>Lodder</surname><given-names>J.C.</given-names></name><name><surname>Zlotkin</surname><given-names>E.</given-names></name><name><surname>Kits</surname><given-names>K.S.</given-names></name><name><surname>Burlingame</surname><given-names>A.L.</given-names></name></person-group><article-title>&#x003b3;-Conotoxin-PnVIIA, a &#x003b3;-carboxyglutamate-containing peptide agonist of neuronal pacemaker cation currents</article-title><source>Biochemistry</source><year>1998</year><volume>37</volume><fpage>1470</fpage><lpage>1477</lpage><pub-id pub-id-type="doi">10.1021/bi971571f</pub-id><?supplied-pmid 9484216?><pub-id pub-id-type="pmid">9484216</pub-id></element-citation></ref><ref id="B5-marinedrugs-15-00313"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fainzilber</surname><given-names>M.</given-names></name><name><surname>Gordon</surname><given-names>D.</given-names></name><name><surname>Hasson</surname><given-names>A.</given-names></name><name><surname>Spira</surname><given-names>M.E.</given-names></name><name><surname>Zlotkin</surname><given-names>E.</given-names></name></person-group><article-title>Mollusc-specific toxins from the venom of Conus textile neovicarius</article-title><source>FEBS J.</source><year>1991</year><volume>202</volume><fpage>589</fpage><lpage>595</lpage><pub-id pub-id-type="doi">10.1111/j.1432-1033.1991.tb16412.x</pub-id></element-citation></ref><ref id="B6-marinedrugs-15-00313"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rigby</surname><given-names>A.C.</given-names></name><name><surname>Lucas-Meunier</surname><given-names>E.</given-names></name><name><surname>Kalume</surname><given-names>D.E.</given-names></name><name><surname>Czerwiec</surname><given-names>E.</given-names></name><name><surname>Hambe</surname><given-names>B.</given-names></name><name><surname>Dahlqvist</surname><given-names>I.</given-names></name><name><surname>Fossier</surname><given-names>P.</given-names></name><name><surname>Baux</surname><given-names>G.</given-names></name><name><surname>Roepstorff</surname><given-names>P.</given-names></name><name><surname>Baleja</surname><given-names>J.D.</given-names></name><etal/></person-group><article-title>A conotoxin from Conus textile with unusual posttranslational modifications reduces presynaptic Ca<sup>2+</sup> influx</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1999</year><volume>96</volume><fpage>5758</fpage><lpage>5763</lpage><pub-id pub-id-type="doi">10.1073/pnas.96.10.5758</pub-id><?supplied-pmid 10318957?><pub-id pub-id-type="pmid">10318957</pub-id></element-citation></ref><ref id="B7-marinedrugs-15-00313"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buczek</surname><given-names>O.</given-names></name><name><surname>Wei</surname><given-names>D.</given-names></name><name><surname>Babon</surname><given-names>J.J.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Fiedler</surname><given-names>B.</given-names></name><name><surname>Chen</surname><given-names>P.</given-names></name><name><surname>Yoshikami</surname><given-names>D.</given-names></name><name><surname>Olivera</surname><given-names>B.M.</given-names></name><name><surname>Bulaj</surname><given-names>G.</given-names></name><name><surname>Norton</surname><given-names>R.S.</given-names></name></person-group><article-title>Structure and sodium channel activity of an excitatory I1-superfamily conotoxin</article-title><source>Biochemistry</source><year>2007</year><volume>46</volume><fpage>9929</fpage><lpage>9940</lpage><pub-id pub-id-type="doi">10.1021/bi700797f</pub-id><?supplied-pmid 17696362?><pub-id pub-id-type="pmid">17696362</pub-id></element-citation></ref><ref id="B8-marinedrugs-15-00313"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terlau</surname><given-names>H.</given-names></name><name><surname>Shon</surname><given-names>K.-J.</given-names></name><name><surname>Grilley</surname><given-names>M.</given-names></name><name><surname>Stocker</surname><given-names>M.</given-names></name><name><surname>St&#x000fc;hmer</surname><given-names>W.</given-names></name><name><surname>Olivera</surname><given-names>B.M.</given-names></name></person-group><article-title>Strategy for rapid immobilization of prey by a fish-hunting marine snail</article-title><source>Nature</source><year>1996</year><volume>381</volume><fpage>148</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1038/381148a0</pub-id><?supplied-pmid 12074021?><pub-id pub-id-type="pmid">12074021</pub-id></element-citation></ref><ref id="B9-marinedrugs-15-00313"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cruz</surname><given-names>L.J.</given-names></name><name><surname>Gray</surname><given-names>W.R.</given-names></name><name><surname>Olivera</surname><given-names>B.M.</given-names></name><name><surname>Zeikus</surname><given-names>R.D.</given-names></name><name><surname>Kerr</surname><given-names>L.</given-names></name><name><surname>Yoshikami</surname><given-names>D.</given-names></name><name><surname>Moczydlowski</surname><given-names>E.</given-names></name></person-group><article-title>Conus geographus toxins that discriminate between neuronal and muscle sodium channels</article-title><source>J. Biol. Chem.</source><year>1985</year><volume>260</volume><fpage>9280</fpage><lpage>9288</lpage><?supplied-pmid 2410412?><pub-id pub-id-type="pmid">2410412</pub-id></element-citation></ref><ref id="B10-marinedrugs-15-00313"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharpe</surname><given-names>I.A.</given-names></name><name><surname>Gehrmann</surname><given-names>J.</given-names></name><name><surname>Loughnan</surname><given-names>M.L.</given-names></name><name><surname>Thomas</surname><given-names>L.</given-names></name><name><surname>Adams</surname><given-names>D.A.</given-names></name><name><surname>Atkins</surname><given-names>A.</given-names></name><name><surname>Palant</surname><given-names>E.</given-names></name><name><surname>Craik</surname><given-names>D.J.</given-names></name><name><surname>Adams</surname><given-names>D.J.</given-names></name><name><surname>Alewood</surname><given-names>P.F.</given-names></name><etal/></person-group><article-title>Two new classes of conopeptides inhibit the &#x003b1;1-adrenoceptor and noradrenaline transporter</article-title><source>Nat. Neurosci.</source><year>2001</year><volume>4</volume><fpage>902</fpage><lpage>907</lpage><pub-id pub-id-type="doi">10.1038/nn0901-902</pub-id><?supplied-pmid 11528421?><pub-id pub-id-type="pmid">11528421</pub-id></element-citation></ref><ref id="B11-marinedrugs-15-00313"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>England</surname><given-names>L.J.</given-names></name><name><surname>Imperial</surname><given-names>J.</given-names></name><name><surname>Jacobsen</surname><given-names>R.</given-names></name><name><surname>Craig</surname><given-names>A.G.</given-names></name><name><surname>Gulyas</surname><given-names>J.</given-names></name><name><surname>Akhtar</surname><given-names>M.</given-names></name><name><surname>Rivier</surname><given-names>J.</given-names></name><name><surname>Julius</surname><given-names>D.</given-names></name><name><surname>Olivera</surname><given-names>B.M.</given-names></name></person-group><article-title>Inactivation of a serotonin-gated ion channel by a polypeptide toxin from marine snails</article-title><source>Science</source><year>1998</year><volume>281</volume><fpage>575</fpage><lpage>578</lpage><pub-id pub-id-type="doi">10.1126/science.281.5376.575</pub-id><pub-id pub-id-type="pmid">9677203</pub-id></element-citation></ref><ref id="B12-marinedrugs-15-00313"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrel</surname><given-names>C.</given-names></name><name><surname>Hocking</surname><given-names>H.G.</given-names></name><name><surname>Reynaud</surname><given-names>M.</given-names></name><name><surname>Upert</surname><given-names>G.</given-names></name><name><surname>Favreau</surname><given-names>P.</given-names></name><name><surname>Biass</surname><given-names>D.</given-names></name><name><surname>Paolini-Bertrand</surname><given-names>M.</given-names></name><name><surname>Peigneur</surname><given-names>S.</given-names></name><name><surname>Tytgat</surname><given-names>J.</given-names></name><name><surname>Gilles</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Identification, structural and pharmacological characterization of &#x003c4;-CnVA, a conopeptide that selectively interacts with somatostatin sst 3 receptor</article-title><source>Biochem. Pharmacol.</source><year>2013</year><volume>85</volume><fpage>1663</fpage><lpage>1671</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2013.03.019</pub-id><?supplied-pmid 23567999?><pub-id pub-id-type="pmid">23567999</pub-id></element-citation></ref><ref id="B13-marinedrugs-15-00313"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kerr</surname><given-names>L.M.</given-names></name><name><surname>Yoshikami</surname><given-names>D.</given-names></name></person-group><article-title>A venom peptide with a novel presynaptic blocking action</article-title><source>Nature</source><year>1984</year><volume>308</volume><fpage>282</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1038/308282a0</pub-id><?supplied-pmid 6608056?><pub-id pub-id-type="pmid">6608056</pub-id></element-citation></ref><ref id="B14-marinedrugs-15-00313"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaas</surname><given-names>Q.</given-names></name><name><surname>Westermann</surname><given-names>J.-C.</given-names></name><name><surname>Halai</surname><given-names>R.</given-names></name><name><surname>Wang</surname><given-names>C.K.L.</given-names></name><name><surname>Craik</surname><given-names>D.J.</given-names></name></person-group><article-title>ConoServer, a database for conopeptide sequences and structures</article-title><source>Bioinformatics</source><year>2007</year><volume>24</volume><fpage>445</fpage><lpage>446</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btm596</pub-id><?supplied-pmid 18065428?><pub-id pub-id-type="pmid">18065428</pub-id></element-citation></ref><ref id="B15-marinedrugs-15-00313"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaas</surname><given-names>Q.</given-names></name><name><surname>Yu</surname><given-names>R.</given-names></name><name><surname>Jin</surname><given-names>A.-H.</given-names></name><name><surname>Dutertre</surname><given-names>S.</given-names></name><name><surname>Craik</surname><given-names>D.J.</given-names></name></person-group><article-title>ConoServer: Updated content, knowledge, and discovery tools in the conopeptide database</article-title><source>Nucleic Acids Res.</source><year>2011</year><fpage>gkr886</fpage><pub-id pub-id-type="doi">10.1093/nar/gkr886</pub-id><?supplied-pmid 22058133?><pub-id pub-id-type="pmid">22058133</pub-id></element-citation></ref><ref id="B16-marinedrugs-15-00313"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olivera</surname><given-names>B.M.</given-names></name><name><surname>Rivier</surname><given-names>J.</given-names></name><name><surname>Scott</surname><given-names>J.K.</given-names></name><name><surname>Hillyard</surname><given-names>D.R.</given-names></name><name><surname>Cruz</surname><given-names>L.J.</given-names></name></person-group><article-title>Conotoxins</article-title><source>J. Biol. Chem.</source><year>1991</year><volume>266</volume><fpage>22067</fpage><lpage>22070</lpage><?supplied-pmid 1939227?><pub-id pub-id-type="pmid">1939227</pub-id></element-citation></ref><ref id="B17-marinedrugs-15-00313"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>D.J.</given-names></name><name><surname>Berecki</surname><given-names>G.</given-names></name></person-group><article-title>Mechanisms of conotoxin inhibition of N-type (Cav2.2) calcium channels</article-title><source>Biochim. Biophys. Acta Biomembr.</source><year>2013</year><volume>1828</volume><fpage>1619</fpage><lpage>1628</lpage><pub-id pub-id-type="doi">10.1016/j.bbamem.2013.01.019</pub-id><?supplied-pmid 23380425?><pub-id pub-id-type="pmid">23380425</pub-id></element-citation></ref><ref id="B18-marinedrugs-15-00313"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bourinet</surname><given-names>E.</given-names></name><name><surname>Zamponi</surname><given-names>G.W.</given-names></name></person-group><article-title>Block of voltage-gated calcium channels by peptide toxins</article-title><source>Neuropharmacology</source><year>2016</year><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2016.10.016</pub-id><?supplied-pmid 27756538?><pub-id pub-id-type="pmid">27756538</pub-id></element-citation></ref><ref id="B19-marinedrugs-15-00313"><label>19.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Hille</surname><given-names>B.</given-names></name></person-group><source>Ion Channels of Excitable Membranes</source><publisher-name>Sinauer</publisher-name><publisher-loc>Sunderland, MA, USA</publisher-loc><year>2001</year><volume>Volume 507</volume></element-citation></ref><ref id="B20-marinedrugs-15-00313"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dolphin</surname><given-names>A.C.</given-names></name></person-group><article-title>Voltage-gated calcium channels and their auxiliary subunits: Physiology and pathophysiology and pharmacology</article-title><source>J. Physiol.</source><year>2016</year><volume>1</volume><fpage>1</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1113/JP272262</pub-id><?supplied-pmid 27273705?><pub-id pub-id-type="pmid">27273705</pub-id></element-citation></ref><ref id="B21-marinedrugs-15-00313"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schroeder</surname><given-names>C.I.</given-names></name><name><surname>Lewis</surname><given-names>R.J.</given-names></name></person-group><article-title>&#x003c9;-conotoxins GVIA, MVIIA and CVID: SAR and clinical potential</article-title><source>Mar. Drugs</source><year>2006</year><volume>4</volume><fpage>193</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.3390/md403193</pub-id></element-citation></ref><ref id="B22-marinedrugs-15-00313"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clapham</surname><given-names>D.E.</given-names></name></person-group><article-title>Calcium signaling</article-title><source>Cell</source><year>1995</year><volume>80</volume><fpage>259</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(95)90408-5</pub-id><pub-id pub-id-type="pmid">7834745</pub-id></element-citation></ref><ref id="B23-marinedrugs-15-00313"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zamponi</surname><given-names>G.W.</given-names></name><name><surname>Striessnig</surname><given-names>J.</given-names></name><name><surname>Koschak</surname><given-names>A.</given-names></name><name><surname>Dolphin</surname><given-names>A.C.</given-names></name></person-group><article-title>The physiology, pathology, and pharmacology of voltage-gated calcium channels and their future therapeutic potential</article-title><source>Pharmacol. Rev.</source><year>2015</year><volume>67</volume><fpage>821</fpage><lpage>870</lpage><pub-id pub-id-type="doi">10.1124/pr.114.009654</pub-id><?supplied-pmid 26362469?><pub-id pub-id-type="pmid">26362469</pub-id></element-citation></ref><ref id="B24-marinedrugs-15-00313"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albillos</surname><given-names>A.</given-names></name><name><surname>Neher</surname><given-names>E.</given-names></name><name><surname>Moser</surname><given-names>T.</given-names></name></person-group><article-title>R-Type Ca<sup>2+</sup> channels are coupled to the rapid component of secretion in mouse adrenal slice chromaffin cells</article-title><source>J. Neurosci.</source><year>2000</year><volume>20</volume><fpage>8323</fpage><lpage>8330</lpage><?supplied-pmid 11069939?><pub-id pub-id-type="pmid">11069939</pub-id></element-citation></ref><ref id="B25-marinedrugs-15-00313"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loane</surname><given-names>D.J.</given-names></name><name><surname>Lima</surname><given-names>P.A.</given-names></name><name><surname>Marrion</surname><given-names>N.</given-names></name></person-group><article-title>V Co-assembly of N-type Ca<sup>2+</sup> and BK channels underlies functional coupling in rat brain</article-title><source>J. Cell Sci.</source><year>2007</year><volume>120</volume><fpage>985</fpage><lpage>995</lpage><pub-id pub-id-type="doi">10.1242/jcs.03399</pub-id><?supplied-pmid 17311846?><pub-id pub-id-type="pmid">17311846</pub-id></element-citation></ref><ref id="B26-marinedrugs-15-00313"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jun</surname><given-names>K.</given-names></name><name><surname>Piedras-Renteria</surname><given-names>E.S.</given-names></name><name><surname>Smith</surname><given-names>S.M.</given-names></name><name><surname>Wheeler</surname><given-names>D.B.</given-names></name><name><surname>Lee</surname><given-names>S.B.</given-names></name><name><surname>Lee</surname><given-names>T.G.</given-names></name><name><surname>Chin</surname><given-names>H.</given-names></name><name><surname>Adams</surname><given-names>M.E.</given-names></name><name><surname>Scheller</surname><given-names>R.H.</given-names></name><name><surname>Tsien</surname><given-names>R.W.</given-names></name><etal/></person-group><article-title>Ablation of P/Q-type Ca<sup>2+</sup> channel currents, altered synaptic transmission, and progressive ataxia in mice lacking the &#x003b1;1A-subunit</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1999</year><volume>96</volume><fpage>15245</fpage><lpage>15250</lpage><pub-id pub-id-type="doi">10.1073/pnas.96.26.15245</pub-id><?supplied-pmid 10611370?><pub-id pub-id-type="pmid">10611370</pub-id></element-citation></ref><ref id="B27-marinedrugs-15-00313"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saegusa</surname><given-names>H.</given-names></name><name><surname>Kurihara</surname><given-names>T.</given-names></name><name><surname>Zong</surname><given-names>S.</given-names></name><name><surname>Kazuno</surname><given-names>A.</given-names></name><name><surname>Matsuda</surname><given-names>Y.</given-names></name><name><surname>Nonaka</surname><given-names>T.</given-names></name><name><surname>Han</surname><given-names>W.</given-names></name><name><surname>Toriyama</surname><given-names>H.</given-names></name><name><surname>Tanabe</surname><given-names>T.</given-names></name></person-group><article-title>Suppression of inflammatory and neuropathic pain symptoms in mice lacking the N-type Ca<sup>2+</sup> channel</article-title><source>EMBO J.</source><year>2001</year><volume>20</volume><fpage>2349</fpage><lpage>2356</lpage><pub-id pub-id-type="doi">10.1093/emboj/20.10.2349</pub-id><?supplied-pmid 11350923?><pub-id pub-id-type="pmid">11350923</pub-id></element-citation></ref><ref id="B28-marinedrugs-15-00313"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bourinet</surname><given-names>E.</given-names></name><name><surname>Altier</surname><given-names>C.</given-names></name><name><surname>Hildebrand</surname><given-names>M.E.</given-names></name><name><surname>Trang</surname><given-names>T.</given-names></name><name><surname>Salter</surname><given-names>M.W.</given-names></name><name><surname>Zamponi</surname><given-names>G.W.</given-names></name></person-group><article-title>Calcium-permeable ion channels in pain signaling</article-title><source>Physiol. Rev.</source><year>2014</year><volume>94</volume><fpage>81</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1152/physrev.00023.2013</pub-id><?supplied-pmid 24382884?><pub-id pub-id-type="pmid">24382884</pub-id></element-citation></ref><ref id="B29-marinedrugs-15-00313"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schroeder</surname><given-names>C.I.</given-names></name><name><surname>Rash</surname><given-names>L.D.</given-names></name><name><surname>Vila-Farr&#x000e9;s</surname><given-names>X.</given-names></name><name><surname>Rosengren</surname><given-names>K.J.</given-names></name><name><surname>Mobli</surname><given-names>M.</given-names></name><name><surname>King</surname><given-names>G.F.</given-names></name><name><surname>Alewood</surname><given-names>P.F.</given-names></name><name><surname>Craik</surname><given-names>D.J.</given-names></name><name><surname>Durek</surname><given-names>T.</given-names></name></person-group><article-title>Chemical Synthesis, 3D Structure, and ASIC Binding Site of the Toxin Mambalgin-2</article-title><source>Angew. Chem. Int. Ed.</source><year>2014</year><volume>53</volume><fpage>1017</fpage><lpage>1020</lpage><pub-id pub-id-type="doi">10.1002/anie.201308898</pub-id><?supplied-pmid 24323786?><pub-id pub-id-type="pmid">24323786</pub-id></element-citation></ref><ref id="B30-marinedrugs-15-00313"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pallaghy</surname><given-names>P.K.</given-names></name><name><surname>Norton</surname><given-names>R.S.</given-names></name><name><surname>Nielsen</surname><given-names>K.J.</given-names></name><name><surname>Craik</surname><given-names>D.J.</given-names></name></person-group><article-title>A common structural motif incorporating a cystine knot and a triple-stranded &#x003b2;-sheet in toxic and inhibitory polypeptides</article-title><source>Protein Sci.</source><year>1994</year><volume>3</volume><fpage>1833</fpage><lpage>1839</lpage><pub-id pub-id-type="doi">10.1002/pro.5560031022</pub-id><?supplied-pmid 7849598?><pub-id pub-id-type="pmid">7849598</pub-id></element-citation></ref><ref id="B31-marinedrugs-15-00313"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sigrist</surname><given-names>C.J.A.</given-names></name><name><surname>Cerutti</surname><given-names>L.</given-names></name><name><surname>Hulo</surname><given-names>N.</given-names></name><name><surname>Gattiker</surname><given-names>A.</given-names></name><name><surname>Falquet</surname><given-names>L.</given-names></name><name><surname>Pagni</surname><given-names>M.</given-names></name><name><surname>Bairoch</surname><given-names>A.</given-names></name><name><surname>Bucher</surname><given-names>P.</given-names></name></person-group><article-title>PROSITE: A documented database using patterns and profiles as motif descriptors</article-title><source>Brief. Bioinform.</source><year>2002</year><volume>3</volume><fpage>265</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.1093/bib/3.3.265</pub-id><?supplied-pmid 12230035?><pub-id pub-id-type="pmid">12230035</pub-id></element-citation></ref><ref id="B32-marinedrugs-15-00313"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sigrist</surname><given-names>C.J.A.</given-names></name><name><surname>De Castro</surname><given-names>E.</given-names></name><name><surname>Cerutti</surname><given-names>L.</given-names></name><name><surname>Cuche</surname><given-names>B.A.</given-names></name><name><surname>Hulo</surname><given-names>N.</given-names></name><name><surname>Bridge</surname><given-names>A.</given-names></name><name><surname>Bougueleret</surname><given-names>L.</given-names></name><name><surname>Xenarios</surname><given-names>I.</given-names></name></person-group><article-title>New and continuing developments at PROSITE</article-title><source>Nucleic Acids Res.</source><year>2012</year><volume>41</volume><fpage>D344</fpage><lpage>D347</lpage><pub-id pub-id-type="doi">10.1093/nar/gks1067</pub-id><?supplied-pmid 23161676?><pub-id pub-id-type="pmid">23161676</pub-id></element-citation></ref><ref id="B33-marinedrugs-15-00313"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellinor</surname><given-names>P.T.</given-names></name><name><surname>Zhang</surname><given-names>J.F.</given-names></name><name><surname>Horne</surname><given-names>W.A.</given-names></name><name><surname>Tsien</surname><given-names>R.W.</given-names></name></person-group><article-title>Structural determinants of the blockade of N-type calcium channels by a peptide neurotoxin</article-title><source>Nature</source><year>1994</year><volume>372</volume><fpage>272</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1038/372272a0</pub-id><?supplied-pmid 7969473?><pub-id pub-id-type="pmid">7969473</pub-id></element-citation></ref><ref id="B34-marinedrugs-15-00313"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olivera</surname><given-names>B.M.</given-names></name><name><surname>Gray</surname><given-names>W.R.</given-names></name><name><surname>Zeikus</surname><given-names>R.</given-names></name><name><surname>McIntosh</surname><given-names>J.M.</given-names></name><name><surname>Varga</surname><given-names>J.</given-names></name><name><surname>Rivier</surname><given-names>J.</given-names></name><name><surname>De Santos</surname><given-names>V.</given-names></name><name><surname>Cruz</surname><given-names>L.J.</given-names></name></person-group><article-title>Peptide neurotoxins from fish-hunting cone snails</article-title><source>Science</source><year>1985</year><volume>230</volume><fpage>1338</fpage><lpage>1343</lpage><pub-id pub-id-type="doi">10.1126/science.4071055</pub-id><?supplied-pmid 4071055?><pub-id pub-id-type="pmid">4071055</pub-id></element-citation></ref><ref id="B35-marinedrugs-15-00313"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCleskey</surname><given-names>E.W.</given-names></name><name><surname>Fox</surname><given-names>A.P.</given-names></name><name><surname>Feldman</surname><given-names>D.H.</given-names></name><name><surname>Cruz</surname><given-names>L.J.</given-names></name><name><surname>Olivera</surname><given-names>B.M.</given-names></name><name><surname>Tsien</surname><given-names>R.W.</given-names></name><name><surname>Yoshikami</surname><given-names>D.</given-names></name></person-group><article-title>Omega-conotoxin: Direct and persistent blockade of specific types of calcium channels in neurons but not muscle</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1987</year><volume>84</volume><fpage>4327</fpage><lpage>4331</lpage><pub-id pub-id-type="doi">10.1073/pnas.84.12.4327</pub-id><?supplied-pmid 2438698?><pub-id pub-id-type="pmid">2438698</pub-id></element-citation></ref><ref id="B36-marinedrugs-15-00313"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Regan</surname><given-names>L.J.</given-names></name><name><surname>Sah</surname><given-names>D.W.Y.</given-names></name><name><surname>Bean</surname><given-names>B.P.</given-names></name></person-group><article-title>Ca<sup>2+</sup> channels in rat central and peripheral neurons: High-threshold current resistant to dihydropyridine blockers and &#x003c9;-conotoxin</article-title><source>Neuron</source><year>1991</year><volume>6</volume><fpage>269</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1016/0896-6273(91)90362-4</pub-id><pub-id pub-id-type="pmid">1847065</pub-id></element-citation></ref><ref id="B37-marinedrugs-15-00313"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olivera</surname><given-names>B.M.</given-names></name><name><surname>Cruz</surname><given-names>L.J.</given-names></name><name><surname>De Santos</surname><given-names>V.</given-names></name><name><surname>LeCheminant</surname><given-names>G.</given-names></name><name><surname>Griffin</surname><given-names>D.</given-names></name><name><surname>Zeikus</surname><given-names>R.</given-names></name><name><surname>McIntosh</surname><given-names>J.M.</given-names></name><name><surname>Galyean</surname><given-names>R.</given-names></name><name><surname>Varga</surname><given-names>J.</given-names></name></person-group><article-title>Neuronal calcium channel antagonists. Discrimination between calcium channel subtypes using omega.-conotoxin from Conus magus venom</article-title><source>Biochemistry</source><year>1987</year><volume>26</volume><fpage>2086</fpage><lpage>2090</lpage><pub-id pub-id-type="doi">10.1021/bi00382a004</pub-id><?supplied-pmid 2441741?><pub-id pub-id-type="pmid">2441741</pub-id></element-citation></ref><ref id="B38-marinedrugs-15-00313"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramilo</surname><given-names>C.A.</given-names></name><name><surname>Zafaralla</surname><given-names>G.C.</given-names></name><name><surname>Nadasdi</surname><given-names>L.</given-names></name><name><surname>Hammerland</surname><given-names>L.G.</given-names></name><name><surname>Yoshikami</surname><given-names>D.</given-names></name><name><surname>Gray</surname><given-names>W.R.</given-names></name><name><surname>Kristipati</surname><given-names>R.</given-names></name><name><surname>Ramachandran</surname><given-names>J.</given-names></name><name><surname>Miljanich</surname><given-names>G.</given-names></name><name><surname>Olivera</surname><given-names>B.M.</given-names></name></person-group><article-title>Novel alpha- and omega-conotoxins from Conus striatus venom</article-title><source>Biochemistry</source><year>1992</year><volume>31</volume><fpage>9919</fpage><lpage>9926</lpage><pub-id pub-id-type="doi">10.1021/bi00156a009</pub-id><?supplied-pmid 1390774?><pub-id pub-id-type="pmid">1390774</pub-id></element-citation></ref><ref id="B39-marinedrugs-15-00313"><label>39.</label><element-citation publication-type="patent"><person-group person-group-type="author"><name><surname>Miljanich</surname><given-names>G.P.</given-names></name><name><surname>Bitner</surname><given-names>R.S.</given-names></name><name><surname>Bowersox</surname><given-names>S.S.</given-names></name><name><surname>Fox</surname><given-names>J.A.</given-names></name><name><surname>Valentino</surname><given-names>K.L.</given-names></name><name><surname>Yamashiro</surname><given-names>D.H.</given-names></name></person-group><article-title>Method of Treating Ischemia-Related Neuronal Damage</article-title><source>U.S. Patent</source><patent>5,051,403 A</patent><day>24</day><month>9</month><year>1991</year></element-citation></ref><ref id="B40-marinedrugs-15-00313"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pallaghy</surname><given-names>P.K.</given-names></name><name><surname>Norton</surname><given-names>R.S.</given-names></name></person-group><article-title>Refined solution structure of &#x003c9;-conotoxin GVIA: Implications for calcium channel binding</article-title><source>J. Pept. Res.</source><year>1999</year><volume>53</volume><fpage>343</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.1034/j.1399-3011.1999.00040.x</pub-id><?supplied-pmid 10231724?><pub-id pub-id-type="pmid">10231724</pub-id></element-citation></ref><ref id="B41-marinedrugs-15-00313"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mould</surname><given-names>J.</given-names></name><name><surname>Yasuda</surname><given-names>T.</given-names></name><name><surname>Schroeder</surname><given-names>C.I.</given-names></name><name><surname>Beedle</surname><given-names>A.M.</given-names></name><name><surname>Doering</surname><given-names>C.J.</given-names></name><name><surname>Zamponi</surname><given-names>G.W.</given-names></name><name><surname>Adams</surname><given-names>D.J.</given-names></name><name><surname>Lewis</surname><given-names>R.J.</given-names></name></person-group><article-title>The &#x003b1;2&#x003b4; auxiliary subunit reduces affinity of &#x003c9;-conotoxins for recombinant N-type (Cav2.2) calcium channels</article-title><source>J. Biol. Chem.</source><year>2004</year><volume>279</volume><fpage>34705</fpage><lpage>34714</lpage><pub-id pub-id-type="doi">10.1074/jbc.M310848200</pub-id><?supplied-pmid 15166237?><pub-id pub-id-type="pmid">15166237</pub-id></element-citation></ref><ref id="B42-marinedrugs-15-00313"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>J.H.</given-names></name><name><surname>Bradley</surname><given-names>E.K.</given-names></name><name><surname>Miljanich</surname><given-names>G.P.</given-names></name><name><surname>Nadasdi</surname><given-names>L.</given-names></name><name><surname>Ramachandran</surname><given-names>J.</given-names></name><name><surname>Basus</surname><given-names>V.J.</given-names></name></person-group><article-title>Solution structure of. omega.-conotoxin GVIA using 2-D NMR spectroscopy and relaxation matrix analysis</article-title><source>Biochemistry</source><year>1993</year><volume>32</volume><fpage>7396</fpage><lpage>7405</lpage><pub-id pub-id-type="doi">10.1021/bi00080a009</pub-id><?supplied-pmid 8338837?><pub-id pub-id-type="pmid">8338837</pub-id></element-citation></ref><ref id="B43-marinedrugs-15-00313"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.-X.</given-names></name><name><surname>Pettus</surname><given-names>M.</given-names></name><name><surname>Gao</surname><given-names>D.</given-names></name><name><surname>Phillips</surname><given-names>C.</given-names></name><name><surname>Bowersox</surname><given-names>S.S.</given-names></name></person-group><article-title>Effects of intrathecal administration of ziconotide, a selective neuronal N-type calcium channel blocker, on mechanical allodynia and heat hyperalgesia in a rat model of postoperative pain</article-title><source>Pain</source><year>2000</year><volume>84</volume><fpage>151</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1016/S0304-3959(99)00197-9</pub-id><pub-id pub-id-type="pmid">10666519</pub-id></element-citation></ref><ref id="B44-marinedrugs-15-00313"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miljanich</surname><given-names>G.P.</given-names></name></person-group><article-title>Ziconotide: Neuronal calcium channel blocker for treating severe chronic pain</article-title><source>Curr. Med. Chem.</source><year>2004</year><volume>11</volume><fpage>3029</fpage><lpage>3040</lpage><pub-id pub-id-type="doi">10.2174/0929867043363884</pub-id><?supplied-pmid 15578997?><pub-id pub-id-type="pmid">15578997</pub-id></element-citation></ref><ref id="B45-marinedrugs-15-00313"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>F.</given-names></name><name><surname>Yan</surname><given-names>Z.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Wu</surname><given-names>Q.</given-names></name><name><surname>Yu</surname><given-names>S.</given-names></name><name><surname>Ding</surname><given-names>J.</given-names></name><name><surname>Dai</surname><given-names>Q.</given-names></name></person-group><article-title>Molecular basis of toxicity of N-type calcium channel inhibitor MVIIA</article-title><source>Neuropharmacology</source><year>2016</year><volume>101</volume><fpage>137</fpage><lpage>145</lpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2015.08.047</pub-id><?supplied-pmid 26344359?><pub-id pub-id-type="pmid">26344359</pub-id></element-citation></ref><ref id="B46-marinedrugs-15-00313"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skov</surname><given-names>M.J.</given-names></name><name><surname>Beck</surname><given-names>J.C.</given-names></name><name><surname>de Kater</surname><given-names>A.W.</given-names></name><name><surname>Shopp</surname><given-names>G.M.</given-names></name></person-group><article-title>Nonclinical safety of ziconotide: An intrathecal analgesic of a new pharmaceutical class</article-title><source>Int. J. Toxicol.</source><year>2007</year><volume>26</volume><fpage>411</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1080/10915810701582970</pub-id><?supplied-pmid 17963128?><pub-id pub-id-type="pmid">17963128</pub-id></element-citation></ref><ref id="B47-marinedrugs-15-00313"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGivern</surname><given-names>J.G.</given-names></name></person-group><article-title>Ziconotide: A review of its pharmacology and use in the treatment of pain</article-title><source>Neuropsychiatr. Dis. Treat.</source><year>2007</year><volume>3</volume><fpage>69</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.2147/nedt.2007.3.1.69</pub-id><?supplied-pmid 19300539?><pub-id pub-id-type="pmid">19300539</pub-id></element-citation></ref><ref id="B48-marinedrugs-15-00313"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kohno</surname><given-names>T.</given-names></name><name><surname>Kim</surname><given-names>J.I.</given-names></name><name><surname>Kobayashi</surname><given-names>K.</given-names></name><name><surname>Kodera</surname><given-names>Y.</given-names></name><name><surname>Maeda</surname><given-names>T.</given-names></name><name><surname>Sato</surname><given-names>K.</given-names></name></person-group><article-title>Three-Dimensional Structure in Solution of the Calcium Channel Blocker omega.-Conotoxin MVIIA</article-title><source>Biochemistry</source><year>1995</year><volume>34</volume><fpage>10256</fpage><lpage>10265</lpage><pub-id pub-id-type="doi">10.1021/bi00032a020</pub-id><?supplied-pmid 7640281?><pub-id pub-id-type="pmid">7640281</pub-id></element-citation></ref><ref id="B49-marinedrugs-15-00313"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nielsen</surname><given-names>K.J.</given-names></name><name><surname>Thomas</surname><given-names>L.</given-names></name><name><surname>Lewis</surname><given-names>R.J.</given-names></name><name><surname>Alewood</surname><given-names>P.F.</given-names></name><name><surname>Craik</surname><given-names>D.J.</given-names></name></person-group><article-title>A consensus structure for &#x003c9;-conotoxins with different selectivities for voltage-sensitive calcium channel subtypes: Comparison of MVIIA, SVIB and SNX-202</article-title><source>J. Mol. Biol.</source><year>1996</year><volume>263</volume><fpage>297</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.1006/jmbi.1996.0576</pub-id><?supplied-pmid 8913308?><pub-id pub-id-type="pmid">8913308</pub-id></element-citation></ref><ref id="B50-marinedrugs-15-00313"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>D.J.</given-names></name><name><surname>Smith</surname><given-names>A.B.</given-names></name><name><surname>Schroeder</surname><given-names>C.I.</given-names></name><name><surname>Yasuda</surname><given-names>T.</given-names></name><name><surname>Lewis</surname><given-names>R.J.</given-names></name></person-group><article-title>&#x003c9;-conotoxin CVID inhibits a pharmacologically distinct voltage-sensitive calcium channel associated with transmitter release from preganglionic nerve terminals</article-title><source>J. Biol. Chem.</source><year>2003</year><volume>278</volume><fpage>4057</fpage><lpage>4062</lpage><pub-id pub-id-type="doi">10.1074/jbc.M209969200</pub-id><?supplied-pmid 12441339?><pub-id pub-id-type="pmid">12441339</pub-id></element-citation></ref><ref id="B51-marinedrugs-15-00313"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atkinson</surname><given-names>R.A.</given-names></name><name><surname>Kieffer</surname><given-names>B.</given-names></name><name><surname>Dejaegere</surname><given-names>A.</given-names></name><name><surname>Sirockin</surname><given-names>F.</given-names></name><name><surname>Lef&#x000e8;vre</surname><given-names>J.-F.</given-names></name></person-group><article-title>Structural and dynamic characterization of &#x003c9;-conotoxin MVIIA: The binding loop exhibits slow conformational exchange</article-title><source>Biochemistry</source><year>2000</year><volume>39</volume><fpage>3908</fpage><lpage>3919</lpage><pub-id pub-id-type="doi">10.1021/bi992651h</pub-id><?supplied-pmid 10747778?><pub-id pub-id-type="pmid">10747778</pub-id></element-citation></ref><ref id="B52-marinedrugs-15-00313"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monje</surname><given-names>V.D.</given-names></name><name><surname>Haack</surname><given-names>J.A.</given-names></name><name><surname>Naisbitt</surname><given-names>S.R.</given-names></name><name><surname>Miljanich</surname><given-names>G.</given-names></name><name><surname>Ramachandran</surname><given-names>J.</given-names></name><name><surname>Nasdasdi</surname><given-names>L.</given-names></name><name><surname>Olivera</surname><given-names>B.M.</given-names></name><name><surname>Hillyard</surname><given-names>D.R.</given-names></name><name><surname>Gray</surname><given-names>W.R.</given-names></name></person-group><article-title>A new Conus peptide ligand for Ca channel subtypes</article-title><source>Neuropharmacology</source><year>1993</year><volume>32</volume><fpage>1141</fpage><lpage>1149</lpage><pub-id pub-id-type="doi">10.1016/0028-3908(93)90008-Q</pub-id><pub-id pub-id-type="pmid">8107968</pub-id></element-citation></ref><ref id="B53-marinedrugs-15-00313"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farr-Jones</surname><given-names>S.</given-names></name><name><surname>Miljanich</surname><given-names>G.P.</given-names></name><name><surname>Nadasdi</surname><given-names>L.</given-names></name><name><surname>Ramachandran</surname><given-names>J.</given-names></name><name><surname>Basus</surname><given-names>V.J.</given-names></name></person-group><article-title>Solution structure of &#x003c9;-conotoxin MVIIC, a high affinity ligand of P-type calcium channels, using1H NMR spectroscopy and complete relaxation matrix analysis</article-title><source>J. Mol. Biol.</source><year>1995</year><volume>248</volume><fpage>106</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1006/jmbi.1995.0205</pub-id><?supplied-pmid 7731037?><pub-id pub-id-type="pmid">7731037</pub-id></element-citation></ref><ref id="B54-marinedrugs-15-00313"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nielsen</surname><given-names>K.J.</given-names></name><name><surname>Adams</surname><given-names>D.</given-names></name><name><surname>Thomas</surname><given-names>L.</given-names></name><name><surname>Bond</surname><given-names>T.</given-names></name><name><surname>Alewood</surname><given-names>P.F.</given-names></name><name><surname>Craik</surname><given-names>D.J.</given-names></name><name><surname>Lewis</surname><given-names>R.J.</given-names></name></person-group><article-title>Structure-activity relationships of &#x003c9;-conotoxins MVIIA, MVIIC and 14 loop splice hybrids at N and P/Q-type calcium channels</article-title><source>J. Mol. Biol.</source><year>1999</year><volume>289</volume><fpage>1405</fpage><lpage>1421</lpage><pub-id pub-id-type="doi">10.1006/jmbi.1999.2817</pub-id><?supplied-pmid 10373375?><pub-id pub-id-type="pmid">10373375</pub-id></element-citation></ref><ref id="B55-marinedrugs-15-00313"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wen</surname><given-names>L.</given-names></name><name><surname>Yang</surname><given-names>S.</given-names></name><name><surname>Qiao</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name><name><surname>Zhou</surname><given-names>W.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Huang</surname><given-names>P.</given-names></name></person-group><article-title>SO-3, a new O-superfamily conopeptide derived from Conus striatus, selectively inhibits N-type calcium currents in cultured hippocampal neurons</article-title><source>Br. J. Pharmacol.</source><year>2005</year><volume>145</volume><fpage>728</fpage><lpage>739</lpage><pub-id pub-id-type="doi">10.1038/sj.bjp.0706223</pub-id><?supplied-pmid 15880145?><pub-id pub-id-type="pmid">15880145</pub-id></element-citation></ref><ref id="B56-marinedrugs-15-00313"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>Y.</given-names></name><name><surname>Tu</surname><given-names>G.</given-names></name><name><surname>Luo</surname><given-names>X.</given-names></name><name><surname>Dai</surname><given-names>Q.</given-names></name><name><surname>Huang</surname><given-names>P.</given-names></name><name><surname>Zhang</surname><given-names>R.</given-names></name></person-group><article-title>Three-dimensional solution structure of &#x003c9;-conotoxin SO<sub>3</sub> determined by1H NMR</article-title><source>Chin. Sci. Bull.</source><year>2003</year><volume>48</volume><fpage>1097</fpage><lpage>1102</lpage><pub-id pub-id-type="doi">10.1007/BF03185760</pub-id></element-citation></ref><ref id="B57-marinedrugs-15-00313"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>R.J.</given-names></name><name><surname>Nielsen</surname><given-names>K.J.</given-names></name><name><surname>Craik</surname><given-names>D.J.</given-names></name><name><surname>Loughnan</surname><given-names>M.L.</given-names></name><name><surname>Adams</surname><given-names>D.A.</given-names></name><name><surname>Sharpe</surname><given-names>I.A.</given-names></name><name><surname>Luchian</surname><given-names>T.</given-names></name><name><surname>Adams</surname><given-names>D.J.</given-names></name><name><surname>Bond</surname><given-names>T.</given-names></name><name><surname>Thomas</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Novel &#x003c9;-conotoxins from Conus catus discriminate among neuronal calcium channel subtypes</article-title><source>J. Biol. Chem.</source><year>2000</year><volume>275</volume><fpage>35335</fpage><lpage>35344</lpage><pub-id pub-id-type="doi">10.1074/jbc.M002252200</pub-id><?supplied-pmid 10938268?><pub-id pub-id-type="pmid">10938268</pub-id></element-citation></ref><ref id="B58-marinedrugs-15-00313"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schroeder</surname><given-names>C.I.</given-names></name><name><surname>Doering</surname><given-names>C.J.</given-names></name><name><surname>Zamponi</surname><given-names>G.W.</given-names></name><name><surname>Lewis</surname><given-names>R.J.</given-names></name></person-group><article-title>N-type calcium channel blockers: Novel therapeutics for the treatment of pain</article-title><source>Med. Chem.</source><year>2006</year><volume>2</volume><fpage>535</fpage><lpage>543</lpage><pub-id pub-id-type="doi">10.2174/157340606778250216</pub-id><?supplied-pmid 17017994?><pub-id pub-id-type="pmid">17017994</pub-id></element-citation></ref><ref id="B59-marinedrugs-15-00313"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>S.</given-names></name><name><surname>Kim</surname><given-names>Y.</given-names></name><name><surname>Back</surname><given-names>S.K.</given-names></name><name><surname>Choi</surname><given-names>H.-W.</given-names></name><name><surname>Lee</surname><given-names>J.Y.</given-names></name><name><surname>Jung</surname><given-names>H.H.</given-names></name><name><surname>Ryu</surname><given-names>J.H.</given-names></name><name><surname>Suh</surname><given-names>H.-W.</given-names></name><name><surname>Na</surname><given-names>H.S.</given-names></name><name><surname>Kim</surname><given-names>H.J.</given-names></name><etal/></person-group><article-title>Analgesic effect of highly reversible &#x003c9;-conotoxin FVIA on N type Ca<sup>2+</sup> channels</article-title><source>Mol. Pain</source><year>2010</year><volume>6</volume><fpage>97</fpage><pub-id pub-id-type="doi">10.1186/1744-8069-6-97</pub-id><?supplied-pmid 21172037?><pub-id pub-id-type="pmid">21172037</pub-id></element-citation></ref><ref id="B60-marinedrugs-15-00313"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fainzilber</surname><given-names>M.</given-names></name><name><surname>Lodder</surname><given-names>J.C.</given-names></name><name><surname>van der Schors</surname><given-names>R.C.</given-names></name><name><surname>Li</surname><given-names>K.W.</given-names></name><name><surname>Yu</surname><given-names>Z.</given-names></name><name><surname>Burlingame</surname><given-names>A.L.</given-names></name><name><surname>Geraerts</surname><given-names>W.P.M.</given-names></name><name><surname>Kits</surname><given-names>K.S.</given-names></name></person-group><article-title>A novel hydrophobic omega-conotoxin blocks molluscan dihydropyridine-sensitive calcium channels</article-title><source>Biochemistry</source><year>1996</year><volume>35</volume><fpage>8748</fpage><lpage>8752</lpage><pub-id pub-id-type="doi">10.1021/bi9602674</pub-id><?supplied-pmid 8679638?><pub-id pub-id-type="pmid">8679638</pub-id></element-citation></ref><ref id="B61-marinedrugs-15-00313"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>K.</given-names></name><name><surname>Sasaki</surname><given-names>T.</given-names></name><name><surname>Sato</surname><given-names>K.</given-names></name><name><surname>Kohno</surname><given-names>T.</given-names></name></person-group><article-title>Three-dimensional solution structure of &#x003c9;-conotoxin TxVII, an L-type calcium channel blocker</article-title><source>Biochemistry</source><year>2000</year><volume>39</volume><fpage>14761</fpage><lpage>14767</lpage><pub-id pub-id-type="doi">10.1021/bi001506x</pub-id><?supplied-pmid 11101291?><pub-id pub-id-type="pmid">11101291</pub-id></element-citation></ref><ref id="B62-marinedrugs-15-00313"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Favreau</surname><given-names>P.</given-names></name><name><surname>Gilles</surname><given-names>N.</given-names></name><name><surname>Lamthanh</surname><given-names>H.</given-names></name><name><surname>Bournaud</surname><given-names>R.</given-names></name><name><surname>Shimahara</surname><given-names>T.</given-names></name><name><surname>Bouet</surname><given-names>F.</given-names></name><name><surname>Laboute</surname><given-names>P.</given-names></name><name><surname>Letourneux</surname><given-names>Y.</given-names></name><name><surname>M&#x000e9;nez</surname><given-names>A.</given-names></name><name><surname>Molg&#x000f3;</surname><given-names>J.</given-names></name><etal/></person-group><article-title>A new &#x003c9;-conotoxin that targets N-type voltage-sensitive calcium channels with unusual specificity</article-title><source>Biochemistry</source><year>2001</year><volume>40</volume><fpage>14567</fpage><lpage>14575</lpage><pub-id pub-id-type="doi">10.1021/bi002871r</pub-id><?supplied-pmid 11724570?><pub-id pub-id-type="pmid">11724570</pub-id></element-citation></ref><ref id="B63-marinedrugs-15-00313"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Violette</surname><given-names>A.</given-names></name><name><surname>Biass</surname><given-names>D.</given-names></name><name><surname>Dutertre</surname><given-names>S.</given-names></name><name><surname>Koua</surname><given-names>D.</given-names></name><name><surname>Piquemal</surname><given-names>D.</given-names></name><name><surname>Pierrat</surname><given-names>F.</given-names></name><name><surname>St&#x000f6;cklin</surname><given-names>R.</given-names></name><name><surname>Favreau</surname><given-names>P.</given-names></name></person-group><article-title>Large-scale discovery of conopeptides and conoproteins in the injectable venom of a fish-hunting cone snail using a combined proteomic and transcriptomic approach</article-title><source>J. Proteom.</source><year>2012</year><volume>75</volume><fpage>5215</fpage><lpage>5225</lpage><pub-id pub-id-type="doi">10.1016/j.jprot.2012.06.001</pub-id><?supplied-pmid 22705119?><pub-id pub-id-type="pmid">22705119</pub-id></element-citation></ref><ref id="B64-marinedrugs-15-00313"><label>64.</label><element-citation publication-type="patent"><person-group person-group-type="author"><name><surname>Miljanich</surname><given-names>G.P.</given-names></name><name><surname>Bitner</surname><given-names>R.S.</given-names></name><name><surname>Bowersox</surname><given-names>S.S.</given-names></name><name><surname>Fox</surname><given-names>J.A.</given-names></name><name><surname>Valentino</surname><given-names>K.L.</given-names></name><name><surname>Yamashiro</surname><given-names>D.H.</given-names></name><name><surname>Tsubokawa</surname><given-names>M.</given-names></name></person-group><article-title>Screening Method for Neuroprotective Compounds</article-title><source>U.S. Patent</source><patent>5,424,218 A</patent><day>4</day><month>11</month><year>1993</year></element-citation></ref><ref id="B65-marinedrugs-15-00313"><label>65.</label><element-citation publication-type="patent"><person-group person-group-type="author"><name><surname>Miljanich</surname><given-names>G.P.</given-names></name><name><surname>Bowersox</surname><given-names>S.S.</given-names></name><name><surname>Fox</surname><given-names>J.A.</given-names></name><name><surname>Valentino</surname><given-names>K.L.</given-names></name><name><surname>Bitner</surname><given-names>R.S.</given-names></name><name><surname>Yamashiro</surname><given-names>D.H.</given-names></name></person-group><article-title>Compositions for Delayed Treatment of Ischemia-Related Neuronal Damage</article-title><source>WO Patent</source><patent>1993010145 A1</patent><day>27</day><month>5</month><year>1993</year></element-citation></ref><ref id="B66-marinedrugs-15-00313"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bai-Song</surname><given-names>L.</given-names></name><name><surname>Fang</surname><given-names>Y.</given-names></name><name><surname>Dong</surname><given-names>Z.</given-names></name><name><surname>Pei-Tang</surname><given-names>H.</given-names></name><name><surname>Cui-Fen</surname><given-names>H.</given-names></name></person-group><article-title>Conopeptides from Conus striatus and Conus textile by cDNA cloning</article-title><source>Peptides</source><year>1999</year><volume>20</volume><fpage>1139</fpage><lpage>1144</lpage><pub-id pub-id-type="doi">10.1016/S0196-9781(99)00116-3</pub-id><pub-id pub-id-type="pmid">10573284</pub-id></element-citation></ref><ref id="B67-marinedrugs-15-00313"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berecki</surname><given-names>G.</given-names></name><name><surname>Motin</surname><given-names>L.</given-names></name><name><surname>Haythornthwaite</surname><given-names>A.</given-names></name><name><surname>Vink</surname><given-names>S.</given-names></name><name><surname>Bansal</surname><given-names>P.</given-names></name><name><surname>Drinkwater</surname><given-names>R.</given-names></name><name><surname>Wang</surname><given-names>C.I.</given-names></name><name><surname>Moretta</surname><given-names>M.</given-names></name><name><surname>Lewis</surname><given-names>R.J.</given-names></name><name><surname>Alewood</surname><given-names>P.F.</given-names></name><etal/></person-group><article-title>Analgesic &#x003c9;-conotoxins CVIE and CVIF selectively and voltage-dependently block recombinant and native N-type calcium channels</article-title><source>Mol. Pharmacol.</source><year>2010</year><volume>77</volume><fpage>139</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1124/mol.109.058834</pub-id><?supplied-pmid 19892914?><pub-id pub-id-type="pmid">19892914</pub-id></element-citation></ref><ref id="B68-marinedrugs-15-00313"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kits</surname><given-names>K.S.</given-names></name><name><surname>Lodder</surname><given-names>J.C.</given-names></name><name><surname>Van Der Schors</surname><given-names>R.C.</given-names></name><name><surname>Li</surname><given-names>K.W.</given-names></name><name><surname>Geraerts</surname><given-names>W.P.M.</given-names></name><name><surname>Fainzilber</surname><given-names>M.</given-names></name></person-group><article-title>Novel &#x003c9;-Conotoxins Block Dihydropyridine-Insensitive High Voltage-Activated Calcium Channels in Molluscan Neurons</article-title><source>J. Neurochem.</source><year>1996</year><volume>67</volume><fpage>2155</fpage><lpage>2163</lpage><pub-id pub-id-type="doi">10.1046/j.1471-4159.1996.67052155.x</pub-id><?supplied-pmid 8863526?><pub-id pub-id-type="pmid">8863526</pub-id></element-citation></ref><ref id="B69-marinedrugs-15-00313"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>Z.-P.</given-names></name><name><surname>Hamid</surname><given-names>J.</given-names></name><name><surname>Doering</surname><given-names>C.</given-names></name><name><surname>Bosey</surname><given-names>G.M.</given-names></name><name><surname>Snutch</surname><given-names>T.P.</given-names></name><name><surname>Zamponi</surname><given-names>G.W.</given-names></name></person-group><article-title>Residue Gly1326 of the N-type calcium channel &#x003b1;1B subunit controls reversibility of &#x003c9;-conotoxin GVIA and MVIIA block</article-title><source>J. Biol. Chem.</source><year>2001</year><volume>276</volume><fpage>15728</fpage><lpage>15735</lpage><pub-id pub-id-type="doi">10.1074/jbc.M100406200</pub-id><?supplied-pmid 11279062?><pub-id pub-id-type="pmid">11279062</pub-id></element-citation></ref><ref id="B70-marinedrugs-15-00313"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schroeder</surname><given-names>C.I.</given-names></name><name><surname>Smythe</surname><given-names>M.L.</given-names></name><name><surname>Lewis</surname><given-names>R.J.</given-names></name></person-group><article-title>Development of small molecules that mimic the binding of &#x003c9;-conotoxins at the N-type voltage-gated calcium channel</article-title><source>Mol. Divers.</source><year>2004</year><volume>8</volume><fpage>127</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1023/B:MODI.0000025656.79632.86</pub-id><?supplied-pmid 15209164?><pub-id pub-id-type="pmid">15209164</pub-id></element-citation></ref><ref id="B71-marinedrugs-15-00313"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baell</surname><given-names>J.B.</given-names></name><name><surname>Duggan</surname><given-names>P.J.</given-names></name><name><surname>Forsyth</surname><given-names>S.A.</given-names></name><name><surname>Lewis</surname><given-names>R.J.</given-names></name><name><surname>Lok</surname><given-names>Y.P.</given-names></name><name><surname>Schroeder</surname><given-names>C.I.</given-names></name></person-group><article-title>Synthesis and biological evaluation of nonpeptide mimetics of &#x003c9;-conotoxin GVIA</article-title><source>Bioorg. Med. Chem.</source><year>2004</year><volume>12</volume><fpage>4025</fpage><lpage>4037</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2004.05.040</pub-id><?supplied-pmid 15246080?><pub-id pub-id-type="pmid">15246080</pub-id></element-citation></ref><ref id="B72-marinedrugs-15-00313"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nadasdi</surname><given-names>L.</given-names></name><name><surname>Yamashiro</surname><given-names>D.</given-names></name><name><surname>Chung</surname><given-names>D.</given-names></name><name><surname>Tarczy-Hornoch</surname><given-names>K.</given-names></name><name><surname>Adriaenssens</surname><given-names>P.</given-names></name><name><surname>Ramachandran</surname><given-names>J.</given-names></name></person-group><article-title>Structure-Activity Analysis of a Conus Peptide Blocker of N-Type Neuronal Calcium Channels</article-title><source>Biochemistry</source><year>1995</year><volume>34</volume><fpage>8076</fpage><lpage>8081</lpage><pub-id pub-id-type="doi">10.1021/bi00025a013</pub-id><?supplied-pmid 7794920?><pub-id pub-id-type="pmid">7794920</pub-id></element-citation></ref><ref id="B73-marinedrugs-15-00313"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menzler</surname><given-names>S.</given-names></name><name><surname>Bikker</surname><given-names>J.A.</given-names></name><name><surname>Horwell</surname><given-names>D.C.</given-names></name></person-group><article-title>Synthesis of a non-peptide analogue of omega-conotoxin MVIIA</article-title><source>Tetrahedron Lett.</source><year>1998</year><volume>39</volume><fpage>7619</fpage><lpage>7622</lpage><pub-id pub-id-type="doi">10.1016/S0040-4039(98)01657-8</pub-id></element-citation></ref><ref id="B74-marinedrugs-15-00313"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menzler</surname><given-names>S.</given-names></name><name><surname>Bikker</surname><given-names>J.A.</given-names></name><name><surname>Suman-Chauhan</surname><given-names>N.</given-names></name><name><surname>Horwell</surname><given-names>D.C.</given-names></name></person-group><article-title>Design and biological evaluation of non-peptide analogues of omega-conotoxin MVIIA</article-title><source>Bioorg. Med. Chem. Lett.</source><year>2000</year><volume>10</volume><fpage>345</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.1016/S0960-894X(99)00699-X</pub-id><pub-id pub-id-type="pmid">10714496</pub-id></element-citation></ref><ref id="B75-marinedrugs-15-00313"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>Z.-X.</given-names></name><name><surname>Cammidge</surname><given-names>A.N.</given-names></name><name><surname>Horwell</surname><given-names>D.C.</given-names></name></person-group><article-title>Dendroid peptide structural mimetics of &#x003c9;-conotoxin MVIIA based on a 2 (1H)-quinolinone core</article-title><source>Tetrahedron</source><year>2000</year><volume>56</volume><fpage>5169</fpage><lpage>5175</lpage><pub-id pub-id-type="doi">10.1016/S0040-4020(00)00179-4</pub-id></element-citation></ref><ref id="B76-marinedrugs-15-00313"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duggan</surname><given-names>P.J.</given-names></name><name><surname>Tuck</surname><given-names>K.L.</given-names></name></person-group><article-title>Bioactive mimetics of conotoxins and other venom peptides</article-title><source>Toxins</source><year>2015</year><volume>7</volume><fpage>4175</fpage><lpage>4198</lpage><pub-id pub-id-type="doi">10.3390/toxins7104175</pub-id><?supplied-pmid 26501323?><pub-id pub-id-type="pmid">26501323</pub-id></element-citation></ref><ref id="B77-marinedrugs-15-00313"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Layer</surname><given-names>R.T.</given-names></name><name><surname>Mcintosh</surname><given-names>J.M.</given-names></name></person-group><article-title>Conotoxins: Therapeutic Potential and Application</article-title><source>Mar. Drugs</source><year>2006</year><volume>4</volume><fpage>119</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.3390/md403119</pub-id></element-citation></ref><ref id="B78-marinedrugs-15-00313"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeager</surname><given-names>R.E.</given-names></name><name><surname>Yoshikami</surname><given-names>D.</given-names></name><name><surname>Rivier</surname><given-names>J.</given-names></name><name><surname>Cruz</surname><given-names>L.J.</given-names></name><name><surname>Miljanich</surname><given-names>G.P.</given-names></name></person-group><article-title>Transmitter release from presynaptic terminals of electric organ: Inhibition by the calcium channel antagonist omega Conus toxin</article-title><source>J. Neurosci.</source><year>1987</year><volume>7</volume><fpage>2390</fpage><lpage>2396</lpage><?supplied-pmid 3112325?><pub-id pub-id-type="pmid">3112325</pub-id></element-citation></ref><ref id="B79-marinedrugs-15-00313"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malmberg</surname><given-names>A.B.</given-names></name><name><surname>Yaksh</surname><given-names>T.L.</given-names></name></person-group><article-title>Effect of continuous intrathecal infusion of &#x003c9;-conopeptides, N-type calcium-channel blockers, on behavior and antinociception in the formalin and hot-plate tests in rats</article-title><source>Pain</source><year>1995</year><volume>60</volume><fpage>83</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1016/0304-3959(94)00094-U</pub-id><pub-id pub-id-type="pmid">7715945</pub-id></element-citation></ref><ref id="B80-marinedrugs-15-00313"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sluka</surname><given-names>K.A.</given-names></name></person-group><article-title>Blockade of N-and P/Q-type calcium channels reduces the secondary heat hyperalgesia induced by acute inflammation</article-title><source>J. Pharmacol. Exp. Ther.</source><year>1998</year><volume>287</volume><fpage>232</fpage><lpage>237</lpage><?supplied-pmid 9765342?><pub-id pub-id-type="pmid">9765342</pub-id></element-citation></ref><ref id="B81-marinedrugs-15-00313"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>W.H.</given-names></name><name><surname>Bennett</surname><given-names>G.J.</given-names></name></person-group><article-title>Synthetic omega-conopeptides applied to the site of nerve injury suppress neuropathic pains in rats</article-title><source>J. Pharmacol. Exp. Ther.</source><year>1995</year><volume>274</volume><fpage>666</fpage><lpage>672</lpage><?supplied-pmid 7636726?><pub-id pub-id-type="pmid">7636726</pub-id></element-citation></ref><ref id="B82-marinedrugs-15-00313"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.-X.</given-names></name><name><surname>Gao</surname><given-names>D.</given-names></name><name><surname>Pettus</surname><given-names>M.</given-names></name><name><surname>Phillips</surname><given-names>C.</given-names></name><name><surname>Bowersox</surname><given-names>S.S.</given-names></name></person-group><article-title>Interactions of intrathecally administered ziconotide, a selective blocker of neuronal N-type voltage-sensitive calcium channels, with morphine on nociception in rats</article-title><source>Pain</source><year>2000</year><volume>84</volume><fpage>271</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1016/S0304-3959(99)00214-6</pub-id><pub-id pub-id-type="pmid">10666532</pub-id></element-citation></ref><ref id="B83-marinedrugs-15-00313"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hannon</surname><given-names>H.E.</given-names></name><name><surname>Atchison</surname><given-names>W.D.</given-names></name></person-group><article-title>Omega-conotoxins as experimental tools and therapeutics in pain management</article-title><source>Mar. Drugs</source><year>2013</year><volume>11</volume><fpage>680</fpage><lpage>699</lpage><pub-id pub-id-type="doi">10.3390/md11030680</pub-id><?supplied-pmid 23470283?><pub-id pub-id-type="pmid">23470283</pub-id></element-citation></ref><ref id="B84-marinedrugs-15-00313"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J.I.</given-names></name><name><surname>Takahashi</surname><given-names>M.</given-names></name><name><surname>Ogura</surname><given-names>A.</given-names></name><name><surname>Kohno</surname><given-names>T.</given-names></name><name><surname>Kudo</surname><given-names>Y.</given-names></name><name><surname>Sato</surname><given-names>K.</given-names></name></person-group><article-title>Hydroxyl group of Tyr13 is essential for the activity of omega-conotoxin GVIA, a peptide toxin for N-type calcium channel</article-title><source>J. Biol. Chem.</source><year>1994</year><volume>269</volume><fpage>23876</fpage><lpage>23878</lpage><?supplied-pmid 7929033?><pub-id pub-id-type="pmid">7929033</pub-id></element-citation></ref><ref id="B85-marinedrugs-15-00313"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lew</surname><given-names>M.J.</given-names></name><name><surname>Flinn</surname><given-names>J.P.</given-names></name><name><surname>Pallaghy</surname><given-names>P.K.</given-names></name><name><surname>Murphy</surname><given-names>R.</given-names></name><name><surname>Whorlow</surname><given-names>S.L.</given-names></name><name><surname>Wright</surname><given-names>C.E.</given-names></name><name><surname>Norton</surname><given-names>R.S.</given-names></name><name><surname>Angus</surname><given-names>J.A.</given-names></name></person-group><article-title>Structure-function relationships of &#x003c9;-conotoxin GVIA Synthesis, structure, calcium channel binding, and functional assay of alanine-substituted analogues</article-title><source>J. Biol. Chem.</source><year>1997</year><volume>272</volume><fpage>12014</fpage><lpage>12023</lpage><pub-id pub-id-type="doi">10.1074/jbc.272.18.12014</pub-id><?supplied-pmid 9115267?><pub-id pub-id-type="pmid">9115267</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="marinedrugs-15-00313-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>&#x003c9;-Conotoxins family pattern (PROSITE ID: PS60004). The pattern is described using the following conventions: &#x02018;x&#x02019; is used for a position where any amino acid is accepted; ambiguities are indicated by listing the acceptable amino acids for a given position, between square parentheses &#x02018;[ ]&#x02019;, i.e., [ALT] stands for Ala or Leu or Thr. Each element in the pattern is separated from its neighbor by a &#x02018;-&#x02018;. Repetition of a pattern element can be indicated by following that element with a numerical value or a numerical range in brackets. Examples: x(2) corresponds to <italic>x-x</italic>, x(1,5) corresponds to <italic>x</italic> or <italic>x-x</italic> or <italic>x-x-x</italic> or <italic>x-x-x-x</italic> or <italic>x-x-x-x-x</italic>.</p></caption><graphic xlink:href="marinedrugs-15-00313-g001"/></fig><fig id="marinedrugs-15-00313-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Structural differences between &#x003c9;-conotoxins. (<bold>A</bold>) Multiple sequence alignment of &#x003c9;-conotoxins colored by conservation in a ramp, from white (not conserved) to dark blue (highly conserved); cysteines involved in disulfide bonds (gray lines) are highlighted in orange, and loops are indicated at the bottom; (<bold>B</bold>) Structural alignment of CVID (model from Swiss Model Repository ID: P58920); SVIB (PDB ID: 1MVJ); GVIA (PDB ID: 2CCO) and MVIIA (PDB ID: 1MVI); the &#x003c9;-conotoxins backbone is represented as a ribbon diagram. Major structural differences in &#x003c9;-conotoxins are labeled as 1 and 2. (<bold>C</bold>) &#x003c9;-conotoxins in ribbon representation with disulfide bonds in stick representation. (<bold>D</bold>) RMSD (&#x000c5;) matrix from &#x003c9;-conotoxins backbone atoms structural alignment.</p></caption><graphic xlink:href="marinedrugs-15-00313-g002"/></fig><table-wrap id="marinedrugs-15-00313-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">marinedrugs-15-00313-t001_Table 1</object-id><label>Table 1</label><caption><p>Classification of conotoxins and their molecular targets <sup>1</sup>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Conotoxin Family</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Molecular Target</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">&#x003b1; (<italic>alpha</italic>)</td><td align="center" valign="middle" rowspan="1" colspan="1">Nicotinic acetylcholine receptors (nAChR)</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B3-marinedrugs-15-00313" ref-type="bibr">3</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">&#x003b3; (g<italic>amma</italic>)</td><td align="center" valign="middle" rowspan="1" colspan="1">Neuronal pacemaker cation currents (inward cation current)</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B4-marinedrugs-15-00313" ref-type="bibr">4</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">&#x003b4; (delta)</td><td align="center" valign="middle" rowspan="1" colspan="1">Voltage-gated sodium (Na<sup>+</sup>) channels</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B5-marinedrugs-15-00313" ref-type="bibr">5</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">&#x003b5; (<italic>epsilon</italic>)</td><td align="center" valign="middle" rowspan="1" colspan="1">Presynaptic calcium (Ca<sup>2+</sup>) channels or G protein-coupled presynaptic receptors</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B6-marinedrugs-15-00313" ref-type="bibr">6</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">&#x003b9; (<italic>iota</italic>)</td><td align="center" valign="middle" rowspan="1" colspan="1">Voltage-gated sodium (Na<sup>+</sup>) channels</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B7-marinedrugs-15-00313" ref-type="bibr">7</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">&#x003ba; (<italic>kappa</italic>)</td><td align="center" valign="middle" rowspan="1" colspan="1">Voltage-gated potassium (K<sup>+</sup>) channels</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B8-marinedrugs-15-00313" ref-type="bibr">8</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">&#x003bc; (<italic>mu</italic>)</td><td align="center" valign="middle" rowspan="1" colspan="1">Voltage-gated sodium (Na<sup>+</sup>)channels</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B9-marinedrugs-15-00313" ref-type="bibr">9</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">&#x003c1; (<italic>rho</italic>)</td><td align="center" valign="middle" rowspan="1" colspan="1">Alpha1-adrenoceptors (GPCR)</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B10-marinedrugs-15-00313" ref-type="bibr">10</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">&#x003c3; (<italic>sigma</italic>)</td><td align="center" valign="middle" rowspan="1" colspan="1">Serotonin-gated ion channels 5-HT3</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B11-marinedrugs-15-00313" ref-type="bibr">11</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">&#x003c4; (<italic>tau</italic>)</td><td align="center" valign="middle" rowspan="1" colspan="1">Somatostatin receptor</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B12-marinedrugs-15-00313" ref-type="bibr">12</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">&#x003c7; (<italic>chi</italic>)</td><td align="center" valign="middle" rowspan="1" colspan="1">Neuronal noradrenaline transporter</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B10-marinedrugs-15-00313" ref-type="bibr">10</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003c9; (<italic>omega</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Voltage-gated calcium (Ca<sub>V</sub>) channels</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B13-marinedrugs-15-00313" ref-type="bibr">13</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p><sup>1</sup> Taken and adapted from <uri xlink:href="www.conoserver.org">www.conoserver.org</uri> [<xref rid="B14-marinedrugs-15-00313" ref-type="bibr">14</xref>,<xref rid="B15-marinedrugs-15-00313" ref-type="bibr">15</xref>].</p></fn></table-wrap-foot></table-wrap><table-wrap id="marinedrugs-15-00313-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">marinedrugs-15-00313-t002_Table 2</object-id><label>Table 2</label><caption><p>Types of calcium channels in vertebrates [<xref rid="B19-marinedrugs-15-00313" ref-type="bibr">19</xref>,<xref rid="B21-marinedrugs-15-00313" ref-type="bibr">21</xref>].</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ca Channel</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Human Gene Name</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Voltage Activation</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">&#x003b1;<sub>1</sub> Subunit</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ca Current</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Ca<sub>V</sub>1.1&#x02013;1.4</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic>CACNA1S; CACNA1C; CACNA1D; CACNA1F</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">HVA</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x003b1;<sub>1S, C, D, F</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">L</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Ca<sub>V</sub>2.1</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic>CACNA1A</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">HVA</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x003b1;<sub>1A</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">P/Q</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Ca<sub>V</sub>2.2</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic>CACNA1B</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">HVA</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x003b1;<sub>1B</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">N</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Ca<sub>V</sub>2.3</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic>CACNA1E</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">HVA</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x003b1;<sub>1E</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">R</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ca<sub>V</sub>3.1&#x02013;3.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>CACNA1G; CACNA1H; CACNA1I</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LVA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003b1;<sub>1G, H, I.</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T</td></tr></tbody></table><table-wrap-foot><fn><p>HVA: High Voltage activated; LVA: Low Voltage activated.</p></fn></table-wrap-foot></table-wrap><table-wrap id="marinedrugs-15-00313-t003" orientation="portrait" position="float"><object-id pub-id-type="pii">marinedrugs-15-00313-t003_Table 3</object-id><label>Table 3</label><caption><p>&#x003c9;-Conotoxins from <italic>Conus</italic> species and their targets.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Specie Conus</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">&#x003c9;-Conotoxin</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Alternative Names</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Target</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Organism</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">IC<sub>50</sub></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><italic>C. geographus</italic></td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">GVIA</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">G6a, SNX-124,</td><td align="center" valign="middle" rowspan="1" colspan="1">Ca<sub>V</sub>2.1</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic>R. norvegicus</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">1.05 &#x003bc;M <sup>1</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B57-marinedrugs-15-00313" ref-type="bibr">57</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ca<sub>V</sub>2.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>R. norvegicus</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.02 pM <sup>1</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B62-marinedrugs-15-00313" ref-type="bibr">62</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GVIB</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">?</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B34-marinedrugs-15-00313" ref-type="bibr">34</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GVIC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">?</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B34-marinedrugs-15-00313" ref-type="bibr">34</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GVIIA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SNX-178</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ca<sub>V</sub>2.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>R. norvegicus</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22.9 nM <sup>1</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B64-marinedrugs-15-00313" ref-type="bibr">64</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GVIIB</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">?</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B34-marinedrugs-15-00313" ref-type="bibr">34</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><italic>C. magus</italic></td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">MVIIA</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">M7a, SNX-111, Ziconotide, Prialt<sup>&#x000ae;</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">Ca<sub>V</sub>2.1</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic>R. norvegicus</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">156 nM <sup>1</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B62-marinedrugs-15-00313" ref-type="bibr">62</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ca<sub>V</sub>2.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>H. sapiens</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.96 nM <sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B59-marinedrugs-15-00313" ref-type="bibr">59</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MVIIB</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SNX-159</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ca<sub>V</sub>2.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>R. norvegicus</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">101 pM <sup>1</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B65-marinedrugs-15-00313" ref-type="bibr">65</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">MVIIC</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">M7c, SNX-230</td><td align="center" valign="middle" rowspan="1" colspan="1">Ca<sub>V</sub>2.1</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic>R. norvegicus</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">600 pM <sup>1</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B57-marinedrugs-15-00313" ref-type="bibr">57</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ca<sub>V</sub>2.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>R. norvegicus</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.0 nM <sup>1</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B57-marinedrugs-15-00313" ref-type="bibr">57</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MVIID</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SNX-238</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">?</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B52-marinedrugs-15-00313" ref-type="bibr">52</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>C. striatus</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SVIA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S6a, SNX-157</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ca<sub>V</sub>2.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>R. norvegicus</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.46 &#x003bc;M <sup>1</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B65-marinedrugs-15-00313" ref-type="bibr">65</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">SVIB</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">S6b, SNX-183</td><td align="center" valign="middle" rowspan="1" colspan="1">Ca<sub>V</sub>2.1</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B38-marinedrugs-15-00313" ref-type="bibr">38</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ca<sub>V</sub>2.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>R. norvegicus</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.09 nM <sup>1</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B65-marinedrugs-15-00313" ref-type="bibr">65</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SO-3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ca<sub>V</sub>2.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">160 nM <sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B45-marinedrugs-15-00313" ref-type="bibr">45</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SO-4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">?</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B66-marinedrugs-15-00313" ref-type="bibr">66</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SO-5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">?</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B66-marinedrugs-15-00313" ref-type="bibr">66</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><italic>C. catus</italic></td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">CVIA</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">C6a, catus-C1b</td><td align="center" valign="middle" rowspan="1" colspan="1">Ca<sub>V</sub>2.1</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic>R. norvegicus</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">850 nM <sup>1</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B57-marinedrugs-15-00313" ref-type="bibr">57</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ca<sub>V</sub>2.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>R. norvegicus</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">560 pM <sup>1</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B57-marinedrugs-15-00313" ref-type="bibr">57</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CVIB</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C6b</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ca<sub>V</sub>2.1<break/>Ca<sub>V</sub>2.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>R. norvegicus</italic><break/><italic>R. norvegicus</italic><break/></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11 nM <sup>1</sup><break/>7.7 nM <sup>1</sup><break/>12 nM <sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B57-marinedrugs-15-00313" ref-type="bibr">57</xref>]<break/>[<xref rid="B57-marinedrugs-15-00313" ref-type="bibr">57</xref>]<break/>[<xref rid="B67-marinedrugs-15-00313" ref-type="bibr">67</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">CVIC</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">C6c</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ca<sub>V</sub>2.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>R. norvegicus</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">31 nM <sup>1</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B57-marinedrugs-15-00313" ref-type="bibr">57</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ca<sub>V</sub>2.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>R. norvegicus</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.6 nM <sup>1</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B57-marinedrugs-15-00313" ref-type="bibr">57</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">CVID</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">AM-336, AM336, leconotide</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ca<sub>V</sub>2.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>R. norvegicus</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">55 &#x003bc;M <sup>1</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B57-marinedrugs-15-00313" ref-type="bibr">57</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ca<sub>V</sub>2.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>R. norvegicus</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">70 pM <sup>1</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B57-marinedrugs-15-00313" ref-type="bibr">57</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CVIE</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ca<sub>V</sub>2.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>R. norvegicus</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.6 nM <sup>2</sup><break/>0.12 nM <sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B67-marinedrugs-15-00313" ref-type="bibr">67</xref>]</td></tr><tr><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">CVIF</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">C6f</td><td align="center" valign="middle" rowspan="1" colspan="1">Ca<sub>V</sub>1.2</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic>R. norvegicus</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;3 &#x003bc;M <sup>2</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B67-marinedrugs-15-00313" ref-type="bibr">67</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Ca<sub>V</sub>1.3</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic>R. norvegicus</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;3 &#x003bc;M <sup>2</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B67-marinedrugs-15-00313" ref-type="bibr">67</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Ca<sub>V</sub>2.2</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic>R. norvegicus</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">19.9 nM/</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B67-marinedrugs-15-00313" ref-type="bibr">67</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.1 nM <sup>2</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B67-marinedrugs-15-00313" ref-type="bibr">67</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ca<sub>V</sub>2.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>R. norvegicus</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;3 &#x003bc;M <sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B67-marinedrugs-15-00313" ref-type="bibr">67</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>C. fulmen</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FVIA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ca<sub>V</sub>2.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>H. sapiens</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11.5 nM <sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B59-marinedrugs-15-00313" ref-type="bibr">59</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>C. radiatus</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RVIA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R6a</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ca<sub>V</sub>2.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>R. norvegicus</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">229 nM <sup>1</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B39-marinedrugs-15-00313" ref-type="bibr">39</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>C. textile</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TxVII</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">L-type</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B60-marinedrugs-15-00313" ref-type="bibr">60</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><italic>C. consors</italic></td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">CnVIIA</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Cn7a, CnVIIH</td><td align="center" valign="middle" rowspan="1" colspan="1">Ca<sub>V</sub>2.1</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic>R. norvegicus</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">179 nM <sup>1</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B62-marinedrugs-15-00313" ref-type="bibr">62</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ca<sub>V</sub>2.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>R. norvegicus</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.3&#x02013;3.7 pM <sup>1</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B62-marinedrugs-15-00313" ref-type="bibr">62</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CnVIIB</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CnVIIG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">?</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B63-marinedrugs-15-00313" ref-type="bibr">63</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CnVIIC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CnVIIE</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">?</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B63-marinedrugs-15-00313" ref-type="bibr">63</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>C. pennaceus</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PnVIA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pn6a</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">?</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>Lymnaea stagnalis</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~5 &#x003bc;M<sup>2</sup>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B68-marinedrugs-15-00313" ref-type="bibr">68</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PnVIB</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pn6b</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">?</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>Lymnaea stagnalis</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~5 &#x003bc;M<sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B68-marinedrugs-15-00313" ref-type="bibr">68</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>C. tulipa</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TVIA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SNX-185</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ca<sub>V</sub>2.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>R. norvegicus</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">228 pM <sup>1</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B65-marinedrugs-15-00313" ref-type="bibr">65</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p><sup>1</sup> Binding/competition assay; <sup>2</sup> Electrophysiological measurements.</p></fn></table-wrap-foot></table-wrap></floats-group></article>